# Subject Index

Page numbers with prefix S are found in Supplement 1 (January).

Page numbers with prefix B are found in Supplement 2 (March).

Page numbers with prefix C are found in Supplement 3 (April).

# A

Abortion, previous maternal, and decreased risk of type 1 diabetes in male offspring, 1063

Acanthosis nigricans, quantitative scale for, 1655

Acarbose

and aminotransferase activity in type 2 diabetes, 1217

effect of fiber intake and meal pattern on gastrointestinal symptoms with, 1227 interaction with digoxin, 860

in type 2 diabetes shows improved glycemic control over 3 years, 960

and weight loss in type 2 diabetic patient, 645

Accidents, in type 1 diabetes, B1

ACE gene polymorphism

and arterial stiffness in type 2 diabetes, 1858 and proliferative retinopathy in type 1 diabetes, 1530

ACE inhibitor(s)

and improved endothelial function in type 1 diabetes, 1536

 -induced cough, in hypertensive type 2 diabetic patients, 1586

ACE insertion/deletion polymorphism, relationship with glomerular hyperfiltration, in type 1 diabetic children and adolescents, 618

Adipose tissue, visceral, age-related increase in, and metabolic risk profile of premenopausal women, 1471

Adiposity

central, associated with multimetabolic syndrome in women with prior gestational diabetes, 876

effects of maternal gestational diabetes on offspring, 1284

leptin and, 1097

Adolescent

blood volumes and pain following capillary punctures in, 1592

diabetes management in, 713

discordance between physician and, in adherence to treatment, 1445

glomerular hyperfiltration and ACE insertion/deletion polymorphism, in type 1 diabetic, 618

improving diabetes control in, 1767 insulin-dependent diabetic, anti-HCV antibodies in, 1587

lispro or regular insulin for multiple injection therapy in, 27

with poorly controlled type 1 diabetes, failure to maintain benefits of homebased intervention in, 1933

with type 1 diabetes

continuous subcutaneous insulin infusion and, 1779

increased Na/Li countertransport activity may help those at risk for developing persistent microalbuminuria, 1158 leptin in, 1590

physical activity and competitive sports in, 1904 urinary excretion of albumin in, 1555 Adults, management of dyslipidemia in, 556

Advanced glycation end products serum levels increased in patients with type 2

serum levels increased in patients with type 2 diabetes and coronary heart disease, 1543

serum levels of, and left ventricular diastolic function in type 1 diabetes, 1186

Advanced glycosylation end products, and hyperglycemia in pathogenesis of complications, B65

African-Americans

children

influence of social environment and year of birth on type 1 diabetes risk in, 78 insulin sensitivity in, 1325

ketoacidosis in obese and lean, immunogenetic analysis suggests different pathogenesis for, 1517

parental history of type 2 diabetes and insulin sensitivity and glucose effectiveness in obese nondiabetic offspring of African-American parents, 1594

sex differences in, and sensitivity to insulin's glucoregulatory and antilipolytic actions, 71

urban

availability of rapid HbA<sub>1c</sub> measurements enhances clinical decision-making, 1415

barriers to provider adherence to management protocols and, 1617

overcoming clinical inertia improves glycemic control in type 2 diabetes in, 1494

with varying degrees of glucose intolerance, cardiovascular risk factors in, 1588

Age

of children with type 1 diabetes, microalbuminuria prevalence varies with, 495

and incidence of type 2 diabetes in Australian aboriginal population, 1993

ALADIN III Study, 1296

Albumin-to-creatinine ratio

and prediction of albumin excretion rate, 1597

and screening for nephropathy, 1599, 1600 Albumin excretion rate

prediction of from albumin-to-creatinine ratio, 1597

urinary

in adolescents with type 1 diabetes, 1555 and body composition and

hyperinsulinemia in normotensive glucose-tolerant adults, 1728 in normoalbuminuric normotensive type

1 diabetes, 1512

Albuminuria

fasting and post-methionine levels of homocysteine in NIDDM, implications for, 125

in type 1 diabetes, increased small dense LDL and intermediate-density lipoprotein and, 1165

Alcohol consumption

relationship to fasting and postload glucose levels, 430

and risk of type 2 diabetes in Japanese men, 1432

 Glucosidase inhibitor, Pneumonia cystoides intestinalis after treatment with, 366 α-Lipoic acid

antioxidant, and treatment of symptomatic polyneuropathy, 1296

treatment, and decreased serum lactate and pyruvate concentrations and improved glucose effectiveness in lean and obese patients with type 2 diabetes, 280

α-Tocopherol, induces leptin expression, 1227,

American Diabetes Association, criteria, concordance with WHO criteria in Northwestern Italian population, 652

American Diabetes Association diagnostic criteria, compared with WHO diagnostic criteria, 1755, 1756

American Diabetes Association, 1997 fasting criteria, concordance with WHO criteria in Mexican subjects, 527

American Diabetes Association Annual Meeting, 1998, 170, 357, 517, 640

American Diabetes Association Annual Meeting, 1999, 1899, 2078

American Indians, glycemic control in, 1802 American Orthopaedic Foot and Ankle Society, diabetic shoe survey, 2099

Aminotransferase activity, and acarbose treatment in type 2 diabetes, 1217

Amputation(s) limb salvage experience in multidisciplinary diabetic foot unit, B97

lower-extremity, 1029 incidence of, 951

prevention by vascular surgery and podiatry collaboration, 679

Amyloid proteins, pancreatic, relation to diabetes, 1590

Amyotrophy, spontaneous recovery of severe weight loss in, 1906

Anemia, blunted erythropoietin response to, in type 1 diabetes, 647

Angioplasty, primary, compared with thrombolysis in acute myocardial infarction, 647

Anti-GAD65 diabetes, ketosis in, 1910 Anti-HCV antibodies, in insulin-dependent diabetic children and adolescents, 1587

Antioxidant status, after improvement in metabolic control in type 2 diabetes, 2083

Antioxidant supplementation, oxidative stress and, in type 1 diabetes, 870, 871 Aortic pulse-wave velocity, correlation between

intima-media thickness of carotid artery and, 1851

Apolipoprotein(B), identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetes, 812

Appetite, reduced, continuous subcutaneous infusion of GLP-1 and, in type 2 diabetes, 1137

Arterial pressure, normal, ACE inhibitors improve endothelial function in type 1 diabetes with, 1536

Arterial stiffness, and ACE gene polymorphism in type 2 diabetes, 1858

Asian Indians, GAD65 antibodies in classification of, 175

Asians, type 2 diabetes in, GAD antibodies in classification of, 1011

Aspirin therapy, S60 Atherosclerosis

augmentation of central arterial pressure in type 1 diabetes, 1722 LDL particle size as independent predictor of glycated LDL level, 1220

macrovascular disease and risk factors for, C21

and serum lipoprotein(a), 93 Atherosclerosis Risk in Communities (ARIC) Study, 767

Atrial natriuretic peptide concentration, decreased plasma, in hyperosmolarhyperglycemic nonketotic syndrome, 1181

Atrial natriuretic peptide-like immunoreactivity excretion, increased urinary, in hyperosmolar-hyperglycemic nonketotic syndrome, 1181

Australian aboriginal population, incidence of type 2 diabetes in, 1993

Autoantibodies

islet, progression to diabetes in relatives with,

red blood cell, with shortened erythrocyte life span as cause of lack of relation between glycosylated hemoglobin and mean blood glucose levels in woman with type 1 diabetes, 2085

Autoantibody, -based risk assessment in family members, 1796

Autoimmune diabetes, type 1A, immunologic 'vaccination" for prevention of, B7 Automobile crashes, in elderly, diabetes and,

Autonomic sympathetic dysfunction, detection, 593

Bacillus Calmette-Guerin vaccine, effect on new-onset type 1 diabetes, 1703 Behavioral science in diabetes, 832 Benzodiazepine, interruption, as cause of

hypoglycemia, 2098 B-Cell(s)

autoimmunity, lack of association with early childhood immunizations, 1694

function, proinsulin and, in lean and obese subjects with and without type 2 diabetes, 609

residual function in type 1 diabetes, cellular immune response to GAD in, 1758, 1759

Birth weight

diabetes in pregnancy and cesarean delivery, 1561

and endothelial function, 2061

low, and glucose intolerance in Swedish middle-aged men, 1043

and type 2 diabetes in Pima Indian children and young adults, 944

of women with gestational diabetes, 1059 Birth year, influence on type 1 diabetes risk in African-American and Latino children, 78 Blood glucose

awareness training, and epinephrine responses to hypoglycemia in type 1 diabetes, 1022

bedside monitoring of in hospitals, S81 contribution of postprandial versus interprandial to HbA1c, in type 1 diabetes on physiologic intensive therapy with lispro at mealtime, 795

fasting, risk factor for cardiovascular death,

intensive policies to improve, and quality of life in type 2 diabetes, 1125

self-monitoring, reliability of, and glycemic control in type 1 diabetes, 854

Blood pressure

ambulatory monitoring of, in pregnant women with type 1 diabetes, 1507 changes in, in normoalbuminuric

normotensive type 1 diabetes, 1512 circadian, during early course of type 1 diabetes, 1151

control of, and quality of life in type 2 diabetes, 1125

high normal, and risk of type 2 diabetes in Japanese men, 1683

systolic, and plasma triglycerides in diabetic peripheral arterial disease, 453 toe, as predictor for outcome in foot ulcers,

147

Body adiposity, leptin and, 1097 **Body composition** 

effect of walking on, in normoglycemic women and women with type 2 diabetes, 555

and urinary albumin excretion and hyperinsulinemia in normotensive glucose-tolerant adults, 1728

Body fat

age-related increase in, and metabolic risk profile of premenopausal women, 1471 thiazolidinedione and, in type 2 diabetes, 288

Body fat distribution

association with fasting insulin and risk of ischemic stroke, 1077

effect of troglitazone on, in type 2 diabetes, 908

and glucose tolerance status, 1938 Body mass index

and C-reactive protein among U.S. adults, 1971

and incidence of type 2 diabetes in Australian aboriginal population, 1993

Body weight, in teenagers and young adults with type 1 diabetes, 1956

Bone density

impact of peripheral neuropathy on, in type 1 diabetes, 827

in type 1 and type 2 diabetes, 1196 Bruneck Study, 1339

diabetes, 1221

Bulimia nervosa, hypersensitivity to regular and intermediate insulin and, in type 1

Calcium antagonists, and cardiovascular risk in diabetes, 1207

Canadians, aboriginal, youth-onset type 2 diabetes associated with HNF1A S319 in,

Capillary whole blood measurement, of islet autoantibodies, 275

Carbohydrate, meal content, effects on insulin requirements in type 1 diabetic patients treated intensively with basal-bolus (ultralente-regular) insulin regimen, 667

Carbohydrate counting, insulin dosage guide for, in type 1 diabetes, 1252

Carbohydrate metabolism, abnormalities of, prevalence in U.S. Army population, 426 Carboxymethyl lysine, not increased in type 2

diabetes without nephropathy, 877 Cardiac autonomic (dys)function in diabetic children, 1845

impaired diurnal, in type 2 diabetes, 2072

Cardiac autonomic neuropathy

asymptomatic coronary artery disease and, in type 2 diabetes, 1745

diagnosis of, 1387, 1388

noninvasive exploration of, 388

Cardiovascular complications, reducing in type 2 diabetes, 1769 Cardiovascular death, fasting blood glucose as

risk factor for, 45

Cardiovascular disease, C14 in Europeans with type 1 diabetes, fiber intake and serum cholesterol levels and,

fasting and post-methionine levels of homocysteine in NIDDM, implications for, 125

glucose as continuous risk factor of mortality due to, 659

hyperglycemia and, C31

impaired fasting glucose and, 1919

impaired glucose tolerance as risk factor for, 920

improving prognosis in, B89 insulin resistance and, C31

risk of, fasting blood glucose and, 1385, 1386

in type 2 diabetes, 1739

Cardiovascular drug metabolism, effects of diabetes on, 982

Cardiovascular events

incident, glucose and, 233

prediction of, in high-risk NIDDM patients,

Cardiovascular Health Study, 1989-1997, 736 Cardiovascular mortality, impaired fasting glucose not a risk factor for, 2103

Cardiovascular resource utilization, simvastatin and, 1771

Cardiovascular risk

in African-Americans with varying degrees of glucose intolerance, 1588

calcium antagonists and, 1207

effect of walking on, in normoglycemic women and women with type 2 diabetes, 555

glycemic control and, 1220

improved glycemic control reduces impact of weight gain on, in type 1 diabetes, 1084 and insulin sensitivity in type 2 diabetes, 562 in normocholesterolemic type 2 diabetes,

apolipoprotein(B) identifies dyslipidemic phenotypes associated with, 812

prevalence of diabetes and ethnic differences in, 241

Care

implementing practice guidelines for, using problem-based learning, 1672 improvements in as measured by HbA1c after

physician education project, 1612 improving prospect of, 635

moving from compliance to adherence is not enough, 2090

third-party reimbursement for, \$105 Carotid artery, intima-media thickness of, correlation with aortic pulse-wave velocity

in type 2 diabetes, 1851 Carotid atherosclerosis, plasma glucose in

normal range not associated with, 1339 Celiac disease, no effect of gluten-free diet on metabolic control of type 1 diabetes in patients with, 1747

Centers for Disease Control and Prevention-

Managed Care Workshop, 1734

Central adiposity, associated with multimetabolic syndrome in women with prior gestational diabetes, 876

Central arterial pressure, augmentation of, in type 1 diabetes, 1722

Central pontine myelinolysis, 998 Cesarean delivery, in diabetes, 1561 Children

African-American

influence of social environment and year of birth on type 1 diabetes risk in, 78 insulin sensitivity in, 1325

blood volumes and pain following capillary punctures in, 1592

cardiac autonomic dysfunction in diabetic, 1845

with diabetes, care of in school/day care setting, 163, S94 poor metabolic control and decreased

growth velocity in, 1012 enteroviral RNA and IgM antibodies in early

pregnancy and risk for childhood-onset IDDM in, 364 Finnish, onset age of type 1 diabetes in, 1066

glomerular hyperfiltration and ACE insertion/deletion polymorphism, in type 1 diabetic, 618

health promotion and risk factors in, 189 insulin-dependent diabetic, anti-HCV antibodies in, 1587

ketoacidosis prevention program for, 7 Latino, influence of social environment and year of birth on type 1 diabetes risk in,

male, previous maternal abortion, longer gestation, and younger maternal age decrease risk of type 1 diabetes in, 1063

memory and metabolic control in, 1239 Mexican-American, risk factors in lowincome, 203

perinatal risk factors for type 1 diabetes in, 1698

Pima Indian, birth weight, type 2 diabetes, and insulin resistance in, 944

prepubertal with type 1 diabetes, counterregulation during spontaneous nocturnal hypoglycemia in, 1144 with type 1 diabetes

conventional versus intensive therapy in, 1318

8 mm needles reduce risk of intramuscular injections in, 1621

leptin in, 1590 microalbuminuria prevalence varies with age, sex, and puberty in, 495

pen injectors versus insulin syringes in, 137

perinatal and neonatal determinants of, 928

physical activity and competitive sports in. 1904

predictors of change in

neuropsychological profiles of, 1438 very young, with type 1 diabetes, clinical, autoimmune, and genetic characteristics of, 1950

Chinese

cultural adaptations of quality-of-life measure for, 1216

young patients with type 2 diabetes, plasma insulin, growth hormone, cortisol, and central obesity among, 1450

Cholesterol

HDL, subfractions and risk of developing type 2 diabetes among Pima Indians,

LDL, analytic accuracy of calculated concentrations of, 371, 372

Cholinesterase, as marker of metabolic

serum levels of, and cardiovascular disease in Europeans with type 1 diabetes, B21 troglitazone increases levels of HDL, 355

syndrome, 1381, 1382 Chylomicrons, postprandial serum, effect of oxidized lipids on oxidized lipid levels in.

Circadian blood pressure, during early course of type 1 diabetes, 1151

Circulating intercellular adhesion molecule 1, smoking and increased levels of, in young type 1 diabetic patients, 1871

Clozapine, association with ketoacidosis in treatment with, 176

Coagulation, abnormalities of, in insulin resistance, C25

Cognitive function, effects of repeated hypoglycemia on, 1273

Complications, 1364 AGEs and hyperglycemia in pathogenesis of,

B65 chronic, in patients with newly progressing

autoimmune type 1 diabetes, 1347 eating habits, body weight, and insulin misuse in teenagers and young adults with type 1 diabetes, 1956

epidemiology of, 99 genetics and prediction of, in type 1 diabetes, B53

pathogenesis of in type 2 diabetes, 1209 and quality of life in type 2 diabetes, 1125 risk of infectious, perioperative glycemic control and, 1408

screening for, in HMO setting, 208 vascular, inflammation and, 1927

Concurrent care, \$101 Consensus Development Conference on Diabetic Foot Wound Care, 1354

Continuing medical education, short-term impact of, on providers' attitudes toward treatment, 1929

Continuous subcutaneous insulin infusion, 1779, 587

Control, prevalence of patients reaching target of good, 2092

Coronary arteriosclerosis,

hyperhomocysteinemia as risk factor for, in Japanese patients with type 2 diabetes,

Coronary artery disease

asymptomatic and cardiac autonomic neuropathy and

diabetic nephropathy in type 2 diabetes, 1745 screening for, 1393

glucose intolerance and risk of, 1262

high levels of circulating proinflammatory cytokines and leptin in urban Indians, 363

improving prognosis in, B89

in Japanese-American men, visceral adiposity and, 1808

Konjac-mannan improves glycemia and associated risk factors for, 913 serum levels of AGEs increased in patients with type 2 diabetes and, 1543

soluble L-selectin as marker for, in type 2 diabetes, 2044

Correctional institutions, management of diabetes in, S92

Cortisol, and central obesity among young Chines type 2 diabetic patients, 1450 Cost(s)

of foot ulcers, 382

incremental medical care, of type 2 diabetes during first 8 years after diagnosis, 1116

C-reactive protein, body mass index, and diabetes among U.S. adults, 1971

Creatinine clearance, high-dose vitamin E supplementation and, in type 1 diabetes, 1245

Cyclosporine nephrotoxicity, in type 1 diabetes,

Cystic fibrosis, -related diabetes, HbA1c, determination, and clinical decisionmaking in, 1008, 1009

Cytotoxicity, against neuroblastoma cells, specific fiber deficits in sensorimotor polyneuropathy correspond to, 1839

Dead-in-bed syndrome, in young diabetic patients, B40

Deafness, prevalence increased in patients with type 2 diabetes in the Netherlands, 180 DECODE Study, 1667

Depression

comorbid, in older diabetic Mexican Americans, health burden associated with, 56

in diabetic adults, 448

in parents of children with type 1 diabetes, intensive insulin therapy does not reduce, 1372

and type 2 diabetes, 997 in Japanese men, 1071

Diabetes camps, management of diabetes at, 167, 598

Diabetes control, improving in adolescents, 1767

Diabetes Control and Complications Trial, 99, 1273

implications of, \$24

Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe, 1667 Diabetes interventions, epidemiology of, 99

Diabetes management, office-based intervention to maintain parent-adolescent teamwork in, 713

Diabetes

anti-GAD65

ketosis improved by diet therapy in, 1910 T-cell insulitis in, 615 autoimmune, immunologic "vaccination" for

prevention of, B7

and automobile crashes in elderly, 220 behavioral science in, 832

body mass index, and C-reactive protein among U.S. adults, 1971

childhood, nitrate in drinking water and risk of. 1750

cystic fibrosis-related, HbA1c, determination and clinical decision-making in, 1008, 1009

diagnosis and classification of, report of expert committee on, \$5

during pregnancy, impact of maternal nativity on prevalence of, 729 effects on cardiovascular drug metabolism, 982

and exercise, \$49 glucocorticoid-induced, troglitazone efficacy hospital admission guidelines for, 580 Dyslipidemia impact of new diagnostic criteria for, on different populations, 762 incidence, 773 ketosis-onset, long-term prognosis of islet cell antibody-negative, 1584 late-onset lipoatrophic, 1374 Latino beliefs about, 722 Education level of care among patients with, 533 in Malta, 650 management of in correctional institutions, S92 for, \$105 in HMO, 2011 mortality, 773 Elderly newly diagnosed in Italian patients aged 30-54 years, 50 nutrition recommendations for, \$42 for health care institutions, \$42 predictive model to identify undiagnosed, 213 in pregnancy and cesarean delivery, 1561 prevalence, 773 and cardiovascular risk factors, 241 in offspring of elderly men with known and newly diagnosed diabetes, 1919 2089 research agenda for managed care, 1734 simvastatin and cardiovascular resource utilization in, 1771 standards of care, S32 treatment satisfaction questionnaire, 530 undiagnosed prevalence in U.S. Army population, 426 rapid increase in prevalence of in asymptomatic Hong Kong Chinese, 1751 work disability and, 1105 in young patients, dead-in-bed syndrome and, B40 Diabetes Prevention Program, 543, 623, 1757 clinical trial, 1757 2055 Diabetic foot syndrome, correlation of imaging techniques to histopathology in, 294 Diagnosis ADA criteria for, 366, 367, 368 criteria, consequences of, in older men and women, 1667 crucial points at, B59 impact of new diagnostic criteria for diabetes, on different populations, 762 364 Diet Enterovirus composition, effect on plasma lipids and glucose in type 2 diabetes, 889 eating habits, in teenagers and young adults with type 1 diabetes, 1956 effect of oxidized lipids on oxidized lipid levels in postprandial serum 1084 chylomicrons, 300 low-glycemic index, for type 2 diabetes, improved glycemic control and lipid profile and normalized fibrinolytic activity and, 10 randomized trial of prepared meal program in type 2 diabetes, 191

therapy, and improved ketosis without

Digoxin, interaction with acarbose, 860

Dual-energy X-ray absorptiometry

diabetes, 1910

insulin therapy in case of anti-GAD65

assessment, of fat mass distribution and its

association with insulin resistance

syndrome, 1310 discriminating glucose tolerance status by regions of interest of, 1938 of central obesity and insulin resistance, C10 management of in adults, \$56 Eating habits, in teenagers and young adults with type 1 diabetes, 1956 Edinburgh Artery Study, 453 and metabolic syndrome in women, 1999 self-management, third-party reimbursement in type 1 diabetes, B29 antidiabetic treatment trends in, 736 diabetes and automobile crashes in. 220 diabetes prevalence in offspring of, 1919 GAD antibodies in, 996 Mexican Americans, comorbid depression in diabetic, 56 obese patients with type 2 diabetes, metabolic alterations in, 112 poor-sighted, safety of human insulin in, with type 2 diabetes clinical features of, 1225, 1226 low-dose ethanol predisposes to sulfonylurea-induced low blood glucose, 2037 Employment, hypoglycemia and, \$103 Endothelial (dys)function ACE inhibitors and improved, in type 1 diabetes, 1536 and birth weight, 2061 not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia, 1224 in patients with impaired fasting glucose, in type 2 diabetes, 973 Endothelium-dependent vasodilation, impaired, in type 2 diabetes, 973 Energy balance, leptin and, 1097 Energy restriction, effect on plasma lipids and glucose in type 2 diabetes, 889 Enteroviral RNA, in early pregnancy and risk for childhood-onset IDDM in offspring, antibodies, and islet cell antibodies in type 1 diabetes, 2086 vertically transmitted, and benefits of neonatal immunization, 1760 Epidemiology of Diabetes Complications Study, Epidemiology of Diabetes Interventions and Complications, 99 Epinephrine, responses to hypoglycemia, blood glucose awareness training and, 1022 Erythromycin, gastrokinetic effect of, hyperglycemia attenuates, 339 Erythropoietin response, to anemia in type 1 diabetic patients, 647 Estrogen, exogenous, and changes in retinopathy, 1984 Ethanol, low-dose, predisposes elderly fasted patients with type 2 diabetes to

sulfonylurea-induced low blood glucose,

Ethnic differences, and prevalence of diabetes in cardiovascular risk factors, 241 Euglycemic insulin clamp, insulin sensitivity indices and, 1462 EURODIAB Substudy 2 Study Group, 1698 Europe, perinatal risk factors for type 1diabetes in children in, 1698 European Association for the Study of Diabetes Annual Meeting, 1998, 989, 1364, 1578, 1209 Europeans, with type 1 diabetes, fiber intake, serum cholesterol levels, and cardiovascular disease in, B21 Exercise, 517 and diabetes, \$49 effects of aerobic or resistance, on glucose tolerance and plasma insulin levels in obese men, 684 and oxygen uptake kinetic response in women with type 2 diabetes, 1640 and sulfonylureas, and glucose homeostasis in type 2 diabetes, 1647 walking, effect on cardiovascular risk factors and body composition in normoglycemic women and women with type 2 diabetes, 555 Exercise training, effect on doses of oral agents and insulin, 1754 Exogenous estrogen, and changes in retinopathy, 1984 Factor VIII, relation to incident diabetes, 767 Family history, of diabetes, hyperinsulinemia and development of type 2 diabetes independently of, 86 Fasting blood glucose day-to-day variability of, in newly diagnosed type 2 diabetes, 394 and glycated hemoglobin, in predicting likelihood of diabetes in community. 1908 impaired, 399 level, relationship to sex and alcohol consumption, 430 as parameter of glycemic control in non-insulin-using patients with type 2 diabetes, 904 and risk of cardiovascular disease, 1385, 1386 risk factor for cardiovascular death, 45 central abdominal, postmenopausal hormone replacement therapy and, 1401 distribution, thiazolidinedione and, in type 2 diabetes, 288 Fat mass distribution, dual-energy X-ray absorptiometry assessment of, 1310 Fat replacers, role in nutrition therapy, S90 Fatty acids, metformin and, 179 Ferritin, serum concentration among U.S. adults, 1978 Fiber intake and cardiovascular disease in Europeans with type 1 diabetes, B21 effect on gastrointestinal symptoms with acarbose, 1227

Fibrinolysis, abnormalities of, in insulin

diet in type 2 diabetes and, 10

Filipinos, with type 1 diabetes, GAD65

Fibrinolytic activity, normalized, low-glycemic

antibodies and tyrosine phosphatase-like

resistance, C25

molecule IA-2ic in, 1458 Finland

children in, onset age of type 1 diabetes in, 1066

glycemic control in diabetic patients in, 575 men, smoking and diabetes risk in, 1821 Folate deficiency, is pregnancy in diabetic

women associated with, 1017 Food labeling, S88

Foot, insensate, sources of discrepancies in use of Semmes-Weinstein monofilament, 598 Foot care

clinical correlates of plantar pressure among diabetic veterans, 965

preventive, S54

Foot ulcers

American Orthopaedic Foot and Ankle Society diabetic shoe survey, 2099 causal pathways for incident, 157

Consensus Development Conference on Diabetic Foot Wound Care, 1354

determining an episode of care using claims data, 1110 early identification of, micro lightguide

spectrophotometer and, 1292 healing using standard treatment, 693

incidence, outcomes, and cost of, 382 insulin-treated type 2 diabetic subjects and risk of, 1379

limb salvage experience in multidisciplinary diabetic foot unit, B97

and lower-extremity amputations, 1029 multidisciplinary approach to management of recurrent, in Lithuania, 1428

plantar pressures elevated in neuroischemic and in neuropathic diabetic foot, 1966 prevention of amputation by vascular surgery

and podiatry collaboration, 679 risk factors for, 1036

transcutaneous oxygen tension and toe blood pressure as predictors for outcome in,

Fructosamine, and obesity, 1596 Funagata Diabetes Study, 920 Fundoscopy, for diagnosis of Wolfram syndrome in type 1 diabetes, 1376

G GAD

antibodies

in classification of Asian type 2 diabetes, 1011

in elderly men in different categories of glucose tolerance, 996

cellular immune response to, in type 1 diabetes with residual B-cell function, 1758, 1759

-65 antibodies

in classification of Asian Indian diabetic subjects, 175

present at diagnosis of diabetes predict need for insulin treatment, 409 and tyrosine phosphatase-like molecule IA-2ic in Filipino type 1 diabetic

patients, 1458 Gastrectomy, as cure for gastroparesis, 1000, 1920, 1921

Gastric bypass, significant improvement in HbA1c in morbidly obese type 2 diabetic patient after, 651

Gastroparesis cured by gastrectomy, 1000, 1920, 1921 natural history of, 503

G825 polymorphism in RAGE gene, association with skin complications in type 2 diabetes, 1745

Genetics

C282Y and H63D mutations of hemochromatosis candidate gene, in type 2 diabetes, 525

phenotypic characteristics of early-onset autosomal-dominant type 2 diabetes unlinked to MODY genes, 253

and prediction of complications in type 1 diabetes, B53

RAGE Gly82Ser polymorphism in microangiopathy, 646

youth-onset type 2 diabetes associated with HNF1A \$319 in aboriginal Canadians,

Gestation, longer, and decreased risk of type 1 diabetes in male offspring, 1063

Gestational diabetes, 873, 874, S74 are women with more likely to have been

bottle-fed?, 1747 birth weight of women with, 1059 effects on offspring adiposity at 4-7 years,

1284 insulin-treated, protein metabolism in, 806 metabolic and immunologic effects of insulin lispro in, 1422

new diagnostic criteria for abnormal glucose homeostasis in women with previous,

screening for, 418, 535, 653, 654 women with prior

central adiposity and multimetabolic syndrome in, 876

early postpartum metabolic assessment in, 1053

Gliclazide, antioxidant effects of, in type 2 diabetes, 528, 529

Glomerular filtration rate, in normoalbuminuric normotensive type 1 diabetes, 1512

Glomerular hyperfiltration, relationship with ACE insertion/deletion polymorphism, in type 1 diabetic children and adolescents,

Glomerulopathy, severity of predicts long-term urinary albumin excretion rate in patients with type 1 diabetes and microalbuminuria, 314

Glucagon-like peptide 1, continuous subcutaneous infusion of, and lower plasma glucose, reduced appetite in type 2 diabetes, 1137

Glucocorticoid-induced diabetes, troglitazone efficacy in, 2088

Glucomannan, and improved glycemia and other risk factors for coronary heart disease in type 2 diabetes, 913

Glucose

and incident cardiovascular events, 233 blood

awareness training, and epinephrine responses to hypoglycemia in type 1 diabetes, 1022

bedside monitoring in hospitals, S81 contribution of postprandial versus interprandial to HbA1c, in type 1 diabetes on physiologic intensive therapy with lispro at mealtime, 795

intensive policies to improve, and quality of life in type 2 diabetes, 1125 lack of relation with glycosylated

hemoglobin, in woman with type 1 diabetes, 2085

reliability of self-monitoring, 854 as continuous risk factor for cardiovascular mortality, 659

effect of energy restriction, weight loss, and diet composition on, in type 2 diabetes,

day-to-day variability of, in newly diagnosed type 2 diabetes, 394 and glycated hemoglobin, in predicting likelihood of diabetes in community,

as parameter of glycemic control in non-insulin-using patients with type 2 diabetes, 904

and postload levels, relationships to sex and alcohol consumption, 430

and progression of impaired glucose tolerance, 369, 370

and risk of cardiovascular disease, 1385,

risk factor for cardiovascular death, 45 fingerstick measurement of blood, correlation with GlucoWatch Biographer glucose results in young subjects with type 1 diabetes, 1708

impaired fasting, 399 and cardiovascular disease, 1919

endothelial dysfunction in, 2055 not a risk factor for cardiovascular disease/mortality, 920, 2103

rapid increase in prevalence of in asymptomatic Hong Kong Chinese,

risk of diabetes in new diagnostic category of. 1490

risk of hypertension in Japanese men, 228 simvastatin and cardiovascular resource utilization in, 1771

increased plasma, high-dose vitamin C supplementation and, 1218

insulin dosage guide to correct blood levels of, in type 1 diabetes, 1252

intravenous, insulin response to correlates with plasma levels of TNF receptor-1,

lower plasma, continuous subcutaneous infusion of GLP-1 and, in type 2 diabetes, 1137

in normal range not associated with carotid atherosclerosis, 1339 upon admission with myocardial infarction, 1827

sulfonylurea-induced low blood, low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to, 2037

transcutaneous measurement of, using nearinfrared spectroscopy during hypoglycemia, 2026

two-hour post-glucose loading plasma, as main determinant for progression from impaired glucose tolerance to diabetes in Hong Kong Chinese, 2096

Glucose control, in type 2 diabetes, C57 Glucose effectiveness

α-lipoic acid treatment improves, in type 2 diabetes, 280

in obese nondiabetic offspring of African-American parents, parental history of type 2 diabetes and, 1594

Glucose homeostasis

abnormal, new diagnostic criteria for in women with previous gestational diabetes, 933

interaction of sulfonylureas and exercise on, 1647

Glucose metabolism, in vitro of cultured and transplanted mouse pancreatic islets microencapsulated by means of a highvoltage electrostatic field, B121

Glucose monitoring, new approaches to, 2078 Glucose tolerance

discriminating, by regions of interest of dualenergy X-ray absorptiometry, 1938 in elderly men, GAD antibodies and, 996

impaired, 399 abnormality in urinary protein excretion in Japanese men with, 823

in African-Americans, and cardiovascular risk factors, 1588

elevated remnant-like lipoprotein particles in, 152

fasting glucose and progression of, 369, 370

low birth weight and, in Swedish middleaged men, 1043

muscle fiber characteristics in postmenopausal women with, 1330

progression from to diabetes, in Hong Kong Chinese, 2096

as risk factor for cardiovascular disease, 920

screening for, 1988

and 23-year risk of coronary heart disease and total mortality, 1262 in West African-origin populations, 434

why is it not a disease?, 883 normal, not associated with carotid

atherosclerosis, 1339 in obese men, effects of aerobic or resistance exercise on, 684

oral testing, insulin sensitivity indices and, 1462

prevalence of impaired, in women with

polycystic ovary syndrome, 141 GlucoWatch Biographer, correlation of fingerstick blood glucose measurements with results of, in young subjects with type 1 diabetes, 1708

y-Glutamyltransferase, as marker of metabolic syndrome, 1381, 1382

Gluten-free diet, no effect on metabolic control of type 1 diabetes in patients with celiac disease, 1747

Glyburide

compared with repaglinide, in treatment of type 2 diabetes, 463

and meal-related glycemic control in type 2 diabetes, 789

Glycated hemoglobin, and fasting plasma glucose, in predicting likelihood of diabetes in community, 1908

Glycemia, tests of, S77 Glycemic control

in adolescent, 713 in American Indians, 1802 and cardiovascular risk, 1220

cotherapy with IGF-1 and insulin improves, in type 1 diabetes, 585

eating habits, body weight, and insulin misuse in teenagers and young adults with type 1 diabetes, 1956

fasting plasma glucose as parameter of, in

non-insulin-using patients with type 2 diabetes, 904

in Finland, 575

immediate feedback of HbA1c levels and improved, 1785

impact of work environment on, 569 improved

and hyperglycemia, effects on macrovascular events in type 2 diabetes, C54

postprandial, with Humalog Mix25, 1258 reduces impact of weight gain on cardiovascular risk factors in type 1

diabetes, 1084

influence of blood glucose self-monitoring on, in type 1 diabetes, 854

influence on zinc urinary excretion in type 1 diabetes, 362

insulin aspart and improved postprandial, 801

low-glycemic diet in type 2 diabetes and, 10 meal-related, by repaglinide and glyburide, in type 2 diabetes, 789

overcoming clinical inertia improves, in urban African-Americans with type 2 diabetes, 1494

perioperative, and risk of infectious complications, 1408

postmenopausal hormone replacement therapy and, 1401

psychosocial variables and, 1918 stress and, in type 1 diabetes, 1278 sustained improvement of by insulin

treatment after 9 years in patients with type 2 diabetes and secondary failure, 1373

trial of acarbose in type 2 diabetes show improved, 960

in type 2 diabetes racial and ethnic differences in, 403 repaglinide with metformin and, 119

Glycemic threshold, for mortality risk, 696 Glycosylated hemoglobin, lack of relation with mean blood glucose levels in woman with type 1 diabetes, 2085

Gonadal androgens, correlation with serum insulin levels, racial differences in, 1524

Growth hormone, and central obesity among young Chinese type 2 diabetic patients,

assay, heterozygous hemoglobin Hamadan affects, 177

availability of rapid measurements of, and enhanced clinical decision-making in urban African-Americans, 1415

contribution of postprandial versus interprandial blood glucose to, in type 1 diabetes on physiologic intensive therapy with lispro at mealtime, 795 determination

and clinical decision-making in cystic fibrosis-related diabetes, 1008, 1009 in patients with hemoglobinopathies, 368, 369

immediate feedback of levels of, and improved glycemic control in type 1 and insulin-treated type 2 diabetic patients,

improvements in diabetic care as measured by. 1612

level, and discordance between physician and adolescent in adherence to treatment, 1445

reproducibility of in health adult population,

significant improvement in, in morbidly obese type 2 diabetic patient after gastric bypass, 651

Health maintenance organization diabetes and disenrollment in, 1487 diabetes management in, 2011

experience with use of metformin for type 2 diabetes in, 38

renal assessment practices and effect of nurse case management on patients of, I

risk and protective factors associated with screening for complications in, 208

Heart rate variability, to determine cardiac autonomic dysfunction in diabetic children, 1845

Hemochromatosis candidate gene, in type 2 diabetes, C282Y and H63D mutations of,

Hemoglobinopathies, and determination of HbA<sub>1c</sub>, 368, 369

Hemostatic variables

and progression of retinopathy after improved metabolic control in type 2 diabetes, 1944

relation to incident diabetes, 767 Hepatocyte nuclear factor-1α

diabetes/MODY3, masquerading as type 1 diabetes, 867 G3195, 524

Hispanic Established Population for the Epidemiologic Study of the Elderly, 56

Histopathology, correlation to imaging techniques in diabetic foot syndrome and clinical suspicion of chronic osteomyelitis,

Homeostasis model assessment

as clinical index of insulin resistance, 1911 in type 2 diabetes treated with sulfonylureas, 818

Homocysteine

acute hyperinsulinemia and reduced concentrations of plasma, 1004

fasting and post-methionine levels of, in **NIDDM**, 125

total plasma, and insulin levels in type 2 diabetic patients with secondary failure to oral agents, 2097

Hong Kong Chinese

rapid increase in prevalence of undiagnosed diabetes and impaired fasting glucose in asymptomatic, 1751

two-hour post-glucose loading plasma plasma is main determinant for progression from impaired glucose tolerance to diabetes in, 2096

Honolulu Heart Program, 1262 Hoorn Study, 1097

Hormone-related exposures, and mortality in women, 248

Hormone replacement therapy, postmenopausal, effects on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes, 1401

Hospitals

admission guidelines for diabetes, S80 bedside blood glucose monitoring in, S81 Hunger, postprandial, hyperglycemia affects perception of, 339

Hypercholesterolemia, endothelial dysfunction not reversed by simvastatin treatment in type 2 diabetic patients with, 1224 Hyperglycemia

and AGEs in pathogenesis of complications,

B65

and attenuation of gastrokinetic effect of erythromycin, 339

cardiovascular diseases and, C31

and improvement of glycemic control, effects on macrovascular events in type 2 diabetes, C54

oral antihyperglycemic agents, and macrovascular risk factors in type 2 diabetes, C41

and perception of postprandial hunger, 339 postprandial, postprandial oxidized lipids and, 1384, 1385

in type 1 diabetes, and optimal administration of lispro, 133

Hyperglycemic hyperosmolar nonketotic syndrome, as initial presentation of type 2 diabetes in young cocaine abuser, 1380

Hyperhomocysteinemia, as risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes, 484

Hyperinsulinemia acute, and reduced plasma homocysteine,

1004 and development of type 2 diabetes independently of family history of diabetes, 86

and parasympathetic neuropathy in type 2 diabetes, 1907

and urinary albumin excretion and body composition in normotensive glucosetolerant adults, 1728

Hyperketonemia, effect on plasma lipid peroxidation levels, 1171

Hyperosmolar-hyperglycemic nonketotic syndrome, increased urinary atrial natriuretic peptide-like immunoreactivity excretion in, 1181

Hypertension in diabetes, B76

risk of in Japanese men, impaired fasting glucose and, 228

and risk of type 2 diabetes in Japanese men, 1683

in type 2 diabetes, ACE inhibitor-induced cough and, 1586

Hypoglycemia

benzodiazepine interruption as cause of, 2098

biopsychobehavioral model of severe, 2018 risk of. 580

blood glucose awareness training and epinephrine responses to, 1022

counterregulation during spontaneous nocturnal, in prepubertal children with type 1 diabetes, 1144

due to folk medicine, 1375

and employment/licensure, \$103 intensive and nonintensive treatment for, in

type 1 diabetes, B43 and maprotiline, in patient with type 1 diabetes, 862

repeated, effects on cognitive function, 1273 risk of nocturnal, lispro and, 1607 risk of severe, 2018

self-management of, 580

severe, continuous subcutaneous insulin

infusion and, 1779

sulfonylurea-induced, low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to, 2037

transcutaneous near-infrared spectroscopy to measure blood glucose during, 2026 unawareness, in type 1 diabetes, 866

# IDDM

childhood-onset, enteroviral RNA and IgM antibodies in early pregnancy and risk

in children, pen injectors versus insulin syringes in, 137

IgM antibodies, in early pregnancy and risk for childhood-onset IDDM in offspring, 364

Imaging techniques, correlation to histopathology in diabetic foot syndrome and clinical suspicion of chronic osteomyelitis, 294

Imipenem, insulin autoimmune syndrome after therapy with, 524

Immunization(s)

early childhood, lack of association with Bcell autoimmunity, 1694

neonatal, vertically transmitted enteroviruses and, 1760

Impaired fasting glucose

and cardiovascular disease, 1919 endothelial dysfunction in, 2055 rapid increase in prevalence of in

asymptomatic Hong Kong Chinese, 1751

risk of diabetes in new diagnostic category of. 1490

simvastatin and cardiovascular resource utilization in, 1771

Incidence, of diabetes, 773

Indians, urban, high levels of circulating proinflammatory cytokines and leptin in,

Infant feeding, and risk of type 1 diabetes, 1961

Inflammation, and vascular complications, 1927

allergy to, lispro and, 1916 continuous subcutaneous infusion of, 1779, 587

cotherapy with IGF-1, and improved glycemic control in type 1 diabetes, 585

euglycemic clamp, and insulin sensitivity indices, 1462

exercise training and, 1754

fasting, association with body fat distribution and risk of ischemic stroke, 1077

fasting serum concentrations of, and QTc duration, 1917

glucoregulatory and antilipolytic actions of, sex difference in African-Americans and sensitivity to, 71

human ultralente, versus NPH insulin, to replace lispro in multiple daily injection regimen, 603

hypersensitivity to regular and intermediate but not to crystallized, as aggravation factor for underlying bulimia nervosa in patient with type 1 diabetes, 1221

implanted pump improved stability of delivery from using new preparation process for infused insulin, 1371

in vivo stability of insulin for, 2089 in young women with unstable type 1 diabetes, possibility of pregnancy and. 1001

infused, improved stability of delivery from implanted pumps using new preparation process for, 1371

intensified therapy

and depressive symptoms in parents of children with type 1 diabetes, 1372 effect of lispro on risk of nocturnal

hypoglycemia during, 1607 LDL particle size in relation to, 1688

levels, in type 2 diabetic patients with secondary failure to oral agents, 2097

and metformin, in patient with uncontrolled diabetes and schizophrenia, 1912

misuse of, in teenagers and young adults with type 1 diabetes, 1956

for multiple injection therapy in adolescence, 27

# NPH

in variable combination with lispro, longterm intensive treatment of type 1 diabetes with, 468

versus human ultralente, to replace lispro in multiple daily injection regimen. 603

pen injectors versus syringes in children with type 1 diabetes, 137

plasma, and central obesity among young Chinese type 2 diabetic patients, 1450 plasma levels of, in obese men, effects of

aerobic or resistance exercise on, 684 plastic insulin dosage guide to correct blood glucose levels out of target range and for

carbohydrate counting in type 1 diabetes, 1252 requirements in type 1 diabetes, meal

carbohydrate content and, 667 response to intravenous glucose correlates with plasma levels of TNF receptor-1,

868 safety of human, in poor-sighted elderly

diabetic patients, 2089 -sensitizing agents, in type 2 diabetes requiring insulin, 1004

serum levels, racial differences in correlation with gonadal androgens and, 1524

-treated type 2 diabetic subjects and risk of foot ulcers, 1379

treatment

new approaches to, 2078

and sustained improvement of glycemic control after 9 years in patients with type 2 diabetes and secondary failure, 1373

very-low-dose, and ketoacidosis, 674 Insulin administration, \$83

Insulin analogs, long-acting, B109 Insulin aspart

absorption kinetics and action profile, 1501 and improved postprandial glycemic control,

Insulin autoimmune syndrome, after therapy with imipenem, 524

Insulin-like growth factor 1

cotherapy with insulin, and improved glycemic control in type 1 diabetes, 585 and progression of retinopathy after

improved metabolic control in type 2 diabetes, 1944

Insulin lispro, 1598

in continuous subcutaneous insulin infusion treatment, 784 contribution of postprandial versus interprandial blood glucose to HbA<sub>1c</sub> in intensive therapy with, 795 and development of proliferative diabetic retinopathy during pregnancy, 874 effect on risk of nocturnal hypoglycemia during intensified insulin therapy, 1607 Humalog Mix25, and improved postprandial glycemic control, 1258 human ultralente versus NPH insulin to replace, 603 long-term intensive treatment of type 1 diabetes with, in variable combination with NPH insulin at mealtime, 468 metabolic and immunologic effects of, in gestational diabetes, 1422 Mix25, as premeal therapy in type 2 diabetes, 459 for multiple injection therapy in adolescence, optimal administration of, in hyperglycemic type 1 diabetes, 133 pregnancy, and retinopathy, 2100, 2101 premixed formulations of, 865 and retinopathy in pregnancy, 1750 in treatment of insulin allergy, 1916 2-year prospective audit of effect of introduction of, 1226 Insulin regimen, basal-bolus (ultralenteregular), meal carbohydrate content effects on insulin requirements in type 1 diabetic patients treated intensively with, Insulin Resistance Atherosclerosis Study, 562, 1688 Insulin resistance, 517 abnormalities of coagulation and fibrinolysis in, C25 and cardiovascular disease, C31 and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke, 1191 dyslipidemia of central obesity and, C10 fasting insulin and, among nondiabetic individuals, 1093 genes and cell biology of, 849 homeostasis model assessment as clinical index of, 1911 in type 2 diabetes treated with sulfonylureas, 818 and hyperglycemic associated risk factors, C38 with impaired insulin secretion, and development of overt diabetes in Werner's syndrome, 2094 leptin and, 1097 and peripheral neuropathy, 1914 role in macrovascular disease in type 2 diabetes, C2 and type 2 diabetes in Pima Indian children and young adults, 944 variants of in nonobese Japanese with type 2 diabetes, 2102 Insulin resistance syndrome dual-energy X-ray absorptiometry assessment, of fat mass distribution and its association with, 1310 leptin and, in type 2 diabetic patients with

parasympathetic neuropathy, 1913

prevalence and correlates of, among Native

Americans, 441

Insulin secretion genes and cell biology of, 849 impaired, with concomitant insulin resistance, and development of overt diabetes in Werner's syndrome, 2094 pancreatic amyloid proteins and, 1590 Insulin sensitivity in African-American children with and without family history of type 2 diabetes, 1325 estimation of from single sample, 1003 indices obtained from oral glucose tolerance testing, 1462 LDL particle size in relation to, 1688 in obese nondiabetic offspring of African-American parents, parental history of type 2 diabetes and, 1594 in type 2 diabetes, 562 variants of in nonobese Japanese with type 2 diabetes, 2102 Insulin therapy and macrovascular risk factors in type 2 diabetes, C45 metformin added to in poorly controlled type 2 diabetes, 854 in type 2 diabetes, 528 use alone as pharmacological treatment for type 2 diabetes, C71 Insulin treatment, islet cell and GAD65 antibodies present at diagnosis of diabetes predict need for, 409 Insulitis in autoimmune-mediated patient originally classified as having type 2 diabetes, 541 T-cell, found in anti-GAD65 diabetes with residual B-cell function, 615 Insurance coverage, racial and ethnic differences in, 1679 impact of type 1 diabetes on, B1 Inter-Tribal Heart Project, 441 Intermittent claudication, walking training for, 198 Internal medicine, residents and diabetes care, 661 Intima-media thickness of carotid artery, correlation with aortic pulsewave velocity in type 2 diabetes, 1851 increased, in newly detected type 2 diabetes, 333 Ischemic stroke insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of, 1191 risk of, associations with fasting insulin and body fat distribution, 1077 Islet autoantibodies capillary whole blood measurement of, 275 progression to diabetes in relatives with, 2049 Islet cell antibodies and enterovirus antibodies in type 1 diabetes, present at diagnosis of diabetes predict need for insulin treatment, 409 Italians, newly diagnosed patients aged 30-54 years, clinical, immunological, and genetic heterogeneity of diabetes in, 50 case of liver dysfunction after 19 months of

treatment with troglitazone, 1382, 1384

men abnormality in urinary protein excretion in 823 alcohol consumption and risk of type 2 diabetes in, 1432 depressive symptoms and occurrence of type 2 diabetes among, 1071 high normal blood pressure, hypertension, and risk of type 2 diabetes in, 1683 impaired fasting glucose and risk of hypertension in, 228 nonobese with type 2 diabetes, insulinsensitive and insulin-resistant variants with type 2 diabetes, hyperhomocysteinemia as risk factor for coronary arteriosclerosis in, 484 Japanese Americans baseline plasma leptin levels and subsequent development of diabetes in, 65 men, visceral adiposity and incident coronary heart disease in, 1808 Ketoacidosis association with clozapine treatment, 176 in children, prevention program for, 7 effect of physician specialty on outcomes in, 1790 meningeal syndrome in, 370, 371 in obese and lean African-Americans, immunogenetic analysis suggests different pathogenesis for, 1517 olanzapine treatment for, 1002 sauna-induced, 1584 therapy of severe, 674 Ketosis improved by diet therapy, in case of anti-GAD65 diabetes, 1910 onset diabetes, long-term prognosis of islet cell antibody-negative, 1584 Kidney function cyclosporine nephrotoxicity in type 1 diabetes, 478 as determinant of increased lipoprotein(a) concentrations, 2033 Kidney transplantation, risks and benefits of, B114 Konjac-mannan, and improved glycemia and other risk factors for coronary heart disease in type 2 diabetes, 913 Lactate concentrations, \( \alpha \)-lipoic acid treatment decreases, in type 2 diabetes, 280 Lactic acidosis incidence in metformin users, 925 metformin and, 1010, 1011 with therapeutic metformin blood level, in low-risk diabetic patient, 178 Laser Doppler imaging, and detection of autonomic sympathetic dysfunction, 593 Latinos beliefs about diabetes, 722

children, social environment and year of

Left ventricular diastolic function, in type 1

Left ventricular hypertrophy, in normotensive

nonalbuminuric NIDDM patients,

with, 1186

birth influence type 1 diabetes risk in,

diabetes, serum levels of AGEs associated

ramipril and, 178

Left ventricular mass, effects of lisinopril and nisoldipine on, 491

Leptin

α-tocopheral induces expression of, 1227, 1228

baseline levels, and subsequent development of diabetes in Japanese Americans, 65 in children and adolescents with type 1 diabetes, 1590

fasting, and insulin resistance among nondiabetic individuals, 1093

high levels of, in urban Indians, 363 and insulin resistance syndrome, in type 2 diabetic patients with parasympathetic neuropathy, 1913

plasma concentrations of, in Pima Indians, 413

and variables of body adiposity, energy balance, and insulin resistance, 1097 Lipid abnormalities, and risk factors for macro-

vascular disease in type 2 diabetes, C6 Lipid concentrations, moderate improvement in metabolic control and, in type 1 diabetes, 546

Lipid levels

blood, in type 2 diabetes, diet and, 1605 oxidized, effect of oxidized lipids on, in postprandial serum chylomicrons, 300

Lipid metabolism, postmenopausal hormone replacement therapy and, 1401

Lipid peroxidation, levels, effect of hyperketonemia on, 1171

Lipid profile, improved, low-glycemic diet in type 2 diabetes and, 10 Lipids

effect of energy restriction, weight loss, and diet composition on, in type 2 diabetes,

increase after solitary pancreas transplantation, 320

oxidized, effect on oxidized lipid levels in postprandial serum chylomicrons, 300 postprandial oxidized, 1384, 1385

Lipoatrophic diabetes, late-onset, 1374 Lipoprotein

elevated remnant-like particles, in impaired glucose tolerance and type 2 diabetes,

intermediate-density, and albuminuria in type 1 diabetes, 1165

profile, and macronutrient intake in type 2 diabetes, 1632

Lipoprotein(a)

increased concentrations, renal disease as determinant of, 2033

levels

metformin and, 859 in obese subjects, troglitazone and, 1752 troglitazone and, 859

and peripheral atherosclerosis, 93 Lisinopril, and nisoldipine, effects on left ventricular mass and function in nephropathy, 491

Lithuania, multidisciplinary approach to management of recurrent foot ulcers in,

Liver disease, in type 2 diabetic patients treated with oral antidiabetic agents, 2067 Liver dysfunction, after troglitazone treatment,

1382, 1384

Low-density lipoproteins increased small dense, with albuminuria in type 1 diabetes, 1165

oxidation, after improvement in metabolic control in type 2 diabetes, 2083

particle size as independent predictor of glycated LDL level, 1220 particle size in relation to insulin, proinsulin,

and insulin sensitivity, 1688 vitamin E supplementation and oxidative damage to DNA and plasma, 1626

Low-income patients, use of automated telephone disease management calls in ethnically diverse sample of, 1302

L-selectin, soluble, as marker for coronary artery disease in type 2 diabetes, 2044

Macronutrient intake, and lipoprotein profile in type 2 diabetes, 1632

Macrosomia, significance of, 1201 Macrovascular disease

effects of hyperglycemia and improvement of glycemic control on, in type 2 diabetes,

evaluation of urinary N-acetyl-β-Dglucosaminidase and, in elderly type 2 diabetic patients, 1882

for atherosclerosis, C21 insulin therapy in type 2 diabetes and, C45

oral antihyperglycemic agents and, in type 2 diabetes, C41

in type 2 diabetes, C6

in type 2 diabetes, natural history of, C2 in young patients with type 1 diabetes, intensive therapy and, B35

Magnesium

moderate improvement in metabolic control and, in type 1 diabetes, 546

plasma concentration of, and progression of retinopathy, 864

Malta, burden of diabetes in, 650

Managed care, research agenda for diabetes in, 1734

Management

of diabetes in correctional institutions, 592 in health maintenance organization, 2011 use of automated telephone disease

management calls in ethnically diverse sample of low-income patients, 1302

Maprotiline, and hypoglycemia, in patient with type 1 diabetes, 862

Maternal age, younger, and decreased risk of type I diabetes in male offspring, 1063

Maternal nativity, impact on prevalence of diabetes during pregnancy among U.S. ethnic groups, 729

Maternal transmission, of type 2 diabetes, 938 Maturity-onset diabetes of the young, genes for, phenotypic characteristics of early-onset autosomal-dominant type 2 diabetes unlinked to, 253

Mauritius, predictors of diabetes in, 399 Meal

carbohydrate content, effects on insulin requirements in type 1 diabetic patients treated intensively with basal-bolus (ultralente-regular) insulin regimen, 667

pattern, effect on gastrointestinal symptoms with acarbose, 1227

program, randomized trial of prepared, in type 2 diabetes, 191 -related glycemic control, by repaglinide and

glyburide, in type 2 diabetes, 789 Medicare, predicting expenditures for, 1660 Memory

conventional versus intensive therapy in children with type 1 diabetes and, 1318 and metabolic control in children, 1239

consequences of new diagnostic criteria in older, 1667

elderly

diabetes prevalence in offspring of, 1919 GAD antibodies in, 996

Finnish, smoking and diabetes risk in, 1821

abnormality in urinary protein excretion in 823

alcohol consumption and risk of type 2 diabetes in, 1432

depressive symptoms and occurrence of type 2 diabetes among, 1071

high normal blood pressure, hypertension, and risk of type 2 diabetes in, 1683

impaired fasting glucose and risk of hypertension in, 228

Japanese-American, visceral adiposity and incident coronary heart disease in, 1808 obese, effects of aerobic or resistance exercise on glucose tolerance and plasma insulin

levels in, 684 Meningeal syndrome, in ketoacidosis, 370, 371 Metabolic alterations, in middle-aged and

elderly obese patients with type 2 diabetes, 112 Metabolic assessment, early postpartum, in

women with prior gestational diabetes, 1053

Metabolic control

continuous subcutaneous insulin infusion and, 1779

effect of moderate improvement in on magnesium and lipid concentrations in type 1 diabetes, 546

and memory in children, 1239 no effect of gluten-free diet on, in type 2 diabetes with celiac disease, 1747

poor, and decreased growth velocity in diabetic children, 1012 problems in minority youth, 700

progression of retinopathy after improved, 1944

in type 1 diabetes, tumor necrosis factor-α and, 1749

in type 2 diabetes, improvement in, and lack of effect on LDL oxidation and antioxidant status, 2083

Metabolic profile, association with sex hormone-binding globulin levels in middle-aged premenopausal women,

Metabolic risk profile, of premenopausal women, age-related increase in visceral adipose tissue and body fat and, 1471

Metabolic syndrome serum y-glutamyltransferase and/or serum cholinesterase as markers of, 1381, 1382 in women, education and, 1999

Metformin

added to insulin therapy in poorly controlled type 2 diabetes, 854

as adjuvant to insulin therapy in type 2 diabetes, 528

efficacy in treatment of NIDDM, 33

and fatty acids, 179 guidelines, 532 incidence of lactic acidosis in users of,925 and insulin, in patient with uncontrolled diabetes and schizophrenia, 1912 and lactic acidosis, 1010, 1011 in low-risk diabetic patient, 178 and lipoprotein(a) levels, 859 with repaglinide, effect on glycemic control in type 2 diabetes, 119 for type 2 diabetes, experience in large HMO, 38 Mexican Americans children, risk factors in low-income, 203 older diabetic, comorbid depression in, 56 Mexico, retinopathy and risk of blindness in, 1905 Miami Community Health Study, 1093 Micro lightguide spectrophotometer, and early identification of foot ulcers, 1292 Microalbuminuria ACE inhibitors improve endothelial function in type 1 diabetes with, 1536 detection of, 307 increased urinary transferrin excretion as predictor of, in type 2 diabetes, 1176 and parasympathetic neuropathy in type 2 diabetes, 1907 persistent, increased Na/Li-countertransport activity may help identify type 1 diabetic adolescents and young adults at risk for developing, 1158 prevalence varies with age, sex, and puberty in children with type 1 diabetes, 495 severity of glomerulopathy predicts longterm urinary albumin excretion rate in patients with type 1 diabetes and, 314 Microangiopathy, RAGE Gly82Ser polymorphism in, 646 Microvascular dysfunction, in non-glabrous skin of type 2 diabetes, 1549 Microvascular reactivity, impaired, as early marker of vasculopathy in type 2 diabetes without microalbuminuria, 1865 MODY. See Maturity-onset diabetes of the Mortality, 773 cardiovascular, glucose as continuous risk factor for, 659 cause-specific, in type 2 diabetes, 756 glucose intolerance and risk of, 1262 and hormone-related exposures in women with diabetes, 248 risk, glycemic threshold for, 696 in type 1 diabetes, B1 Motor speed, conventional versus intensive therapy in children with type 1 diabetes and, 1318 Mouse, glucose metabolism in vitro of cultured and transplanted pancreatic islets Multimetabolic syndrome, and central adiposity in women with prior gestational diabetes, Muscle fiber characteristics, in postmenopausal women with normal or impaired glucose tolerance, 1330 Myocardial ischemia, silent, 1396

Myocardial infarction

plasma glucose upon admission with, 1827

primary angioplasty compared with

thrombolysis in, 647

type 2 diabetes and, 1832

Na/Li-countertransport activity, in identifying type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria, 1158 N-acetyl-β-D-glucosaminidase, evaluation of urinary, and macrovascular disease in elderly type 2 diabetic patients, 1882 Native Americans, prevalence and correlates of insulin resistance among, 441 Necrobiosis lipoidica diabeticorum, tretinoin and, 1753 Needles, 8 mm, and reduced risk of intramuscular injections in children with type 1 diabetes, 1621 Neonatal anthropometric measurements, and risk of childhood-onset type 1 diabetes, Neovascular glaucoma, increased levels of nitric oxide in aqueous humor of diabetic patients with, 861 Nephropathy, 640, S66 antiproteinuric effect of pentoxifylline in, 1006, 1007 association with increased familial risk of stroke, 422 asymptomatic coronary artery disease and, in type 2 diabetes, 1745 effects of lisinopril and nisoldipine on left ventricular mass and function in, 491 screening for, urinary albumin-to-creatinine ratio and, 1599, 1600 Netherlands nitrate in drinking water and risk of childhood diabetes in, 1750 type 2 diabetes in, prevalence of deafness increased in, 180 Neuroblastoma cells, specific fiber deficits in sensorimotor polyneuropathy correspond to cytotoxicity against, 1839 Neuropathy cardiac autonomic asymptomatic coronary artery disease and, in type 2 diabetes, 1745 diagnosis of, 1387, 1388 noninvasive exploration of, 388 clinical correlates of plantar pressure among diabetic veterans, 965 improving prognosis in, B84 and lower-extremity amputations, 1029 painful peripheral, treated with venlafaxine, 1909 parasympathetic leptin and insulin resistance syndrome in, 1913 obesity, microalbuminuria, hyperinsulinemia, and increased PAI-1 activity associated with, 1907 peripheral and bone density in type 1 diabetes, 827 insulin resistance and, 1914 plantar pressures elevated in neuroischemic and in neuropathic diabetic foot, 1966 postural characteristics of, 328 risk factors for severity of diabetic polyneuropathy, 1479 specific fiber deficits in sensorimotor polyneuropathy correspond to cytotoxicity against neuroblastoma cells, 1830 treatment of symptomatic polyneuropathy with antioxidant α-lipoic acid, 1296

use of Semmes-Weinstein monofilament in

Strong Heart Study, 1715 Neuropsychological profiles, of children with type 1 diabetes, predictors of change in, 1438 Nicotinamide, in type 1 diabetes, B16 NIDDM elevated remnant-like lipoprotein particles in, 152 fasting and post-methionine levels of homocysteine in, 125 metformin's efficacy in treatment of, 33 normotensive nonalbuminuric patients with, ramipril and left ventricular hypertrophy and, 178 prediction of cardiovascular events in highrisk, 19 use of metformin for, in large HMO, 38 1992 Singapore National Health Survey, 241 Nisoldipine, and lisinopril, effects on left ventricular mass and function in nephropathy, 491 Nitrate, in drinking water, and risk of childhood diabetes in the Netherlands, 1750 Nitric oxide, increased levels of in aqueous humor of diabetic patients with neovascular glaucoma, 861 Nord-Trøndelag Health Surveys, 1813 Northern California Kaiser Permanente Diabetes Registry, 938 Norwegians, prevalence of obesity and known diabetes in adult, 1813 Nurse case management, of HMO patients, renal assessment practices and, 1 Nutrition, food labeling, \$88 Nutrition recommendations, \$42 for health care institutions, \$46 Nutrition therapy, role of fat replacers in, \$90 Obesity, 517 in African-Americans, immunogenetic analysis suggests different pathogenesis for ketoacidosis in, 1517 association with sex hormone-binding globulin levels in middle-aged premenopausal women, 1875 central, in young Chinese type 2 diabetic patients, 1450 dyslipidemia of central, insulin resistance and, C10 effect of troglitazone on lipoprotein(a) levels in. 1752 gastric bypass and, significant improvement in HbA<sub>1c</sub> in morbidly obese type 2 diabetic patient after, 651 in men, effects of aerobic or resistance exercise on glucose tolerance and plasma insulin levels in, 684 in middle-aged elderly with type 2 diabetes, metabolic alterations in, 112 and parasympathetic neuropathy in type 2 diabetes, 1907 prevalence of, in adult Norwegian population, 1813 and pseudohypoparathyroidism and type 2 diabetes, 523 serum fructosamine and, 1596 treating, in type 2 diabetes, 886 weight change and duration of, in type 2 diabetes, 1266 Olanzapaine, and ketoacidosis, 1002 1,5-anhydroglucitol, glycosuria-related urinary

excretion of, renal tubular function and, 863

Operation Desert Foot, 679

Oral antidiabetic agents, liver disease in type 2 diabetic patients treated with, 2067

Osaka Health Survey, 228, 1432, 1683 Osteomyelitis, chronic, correlation of imaging techniques to histopathology in clinical suspicion of, 294

Outcomes, in ketoacidosis, effect of physician specialty on, 1790

Oxidative damage, to DNA, vitamin E supplementation and, 1626

Oxidative stress

and antioxidant supplementation in type 1 diabetes, 870, 871

meal-generated, 2084

Oxygen uptake kinetic responses, exercise training and, in women with type 2 diabetes, 1640

# P

Pain, following capillary punctures in children and adolescents, 1592

Pancreas transplantation, S82 risks and benefits of, B114 solitary, lipids increase after, 320 Pancreatic amyloid proteins, relation to

diabetes, 1590
Parasympathetic neuropathy, leptin and insulin

resistance syndrome in, 1913 Pentosidine, increased levels of, in type 2

diabetes without nephropathy, 877 Pentoxifylline, antiproteinuric effect of, in nephropathy, 1006, 1007

Perinatal risk factors, for childhood type 1 diabetes in Europe, 1698

Peripheral arterial disease, role of systolic blood pressure and plasma triglycerides in, 453 Peripheral neuropathy, insulin resistance and,

Peripheral neuropathy, insulin resistance a 1914 Peripheral vascular disease, and lower-

extremity amputations, 1029 Pharmacology, need for outcome trials in preventive, 844

Physical activity

in children and adolescents with type 1 diabetes, 1904

correlates in sample of older adults with type 2 diabetes, 706

Physician, discordance between adolescent and, in adherence to treatment, 1445 Pima Indians

children and young adults, birth weight, type
2 diabetes, and insulin resistance in, 944
HDL cholesterol subfractions and risk of
developing type 2 diabetes among 271

developing type 2 diabetes among, 271 plasma leptin concentrations in, 413

Plantar pressure clinical correlates of, among diabetic veterans, 965

elevated in neuroischemic and in neuropathic diabetic foot, 1966 Plasminogen activator inhibitor-1 activity, increased, and parasympathetic

neuropathy in type 2 diabetes, 1907

Pneumonia cystoides intestinalis after treatment
with α-glucosidase inhibitor, 366

Podiatry, and vascular surgery collaboration, and prevention of amputation, 679 Polycystic ovary syndrome, prevalence of

impaired glucose tolerance in, 141 Polyneuropathy risk factors for severity of, 1479 treatment of symptomatic, with antioxidant

α-lipoic acid, 1296 Practice guidelines, for diabetes care using problem-based learning, 1672

Pregnancy diabetes and cesarean delivery, 1561 in diabetic women, folate deficiency and, 1017

effects of maternal gestational diabetes on offspring adiposity, 1284

enteroviral RNA and IgM antibodies in early, and risk for childhood-onset IDDM in offspring, 364

gestational diabetes, 873, 874

are women with more likely to have been bottle-fed?, 1747

impact of maternal nativity on prevalence of diabetes during, 729

insulin lispro

and development of proliferative diabetic retinopathy during, 874

and retinopathy in, 1750, 2100, 2101 metabolic and immunologic effects of insulin lispro in gestational diabetes, 1422

preconception care of women with diabetes, S62

protein metabolism in insulin-treated gestational diabetes, 806

screening for gestational diabetes, 418, 535, 653, 654

with type 1 diabetes

ambulatory blood pressure monitoring in, 1507

improving prognosis in, B104 Prevalence, of diabetes, 773

Prevention

of autoimmune diabetes (type 1A), B7 Diabetes Prevention Program, 543, 623 of pre-type 1 diabetes, B4 of type 1 diabetes, S102

Proinflammatory cytokines, high levels of, in urban Indians, 363

Proinsulin

and β-cell function in lean and obese subjects with and without type 2 diabetes, 609

fasting concentrations of, and prediction of development of type 2 diabetes, 262 LDL particle size in relation to, 1688

Protein metabolism, in insulin-treated gestational diabetes, 806

Pseudohypoparathyroidism, and obesity and type 2 diabetes, 523

Psychosocial variables, in evaluating assessments of glycemic control, 1917 Puberty, in children with type 1 diabetes,

uberty, in children with type 1 diabetes, microalbuminuria prevalence varies with,

Pyruvate concentrations, α-lipoic acid treatment decreases, in type 2 diabetes, 280

. Ic duration, fasting sert

QTc duration, fasting serum insulin concentrations associated with, 1917 Quality of life

measure, cultural adaptations of for Chinese patients, 1216

in type 2 diabetes, affected by complications but not by intensive policies to improve blood glucose or blood pressure control, 1125

# R

Race

differences in correlation with gonadal androgens and serum insulin levels, 1524 differences in health insurance coverage, 1679

in type 2 diabetes, and risk of retinopathy, 779

RAGE gene

G825 polymorphism, association with skin complications in type 2 diabetes, 1745 Gly82Ser polymorphism, in

microangiopathy, 646 Ramipril, and left ventricular hypertrophy, in normotensive nonalbuminuric NIDDM

patients, 178
Renal assessment practices, and effect of nurse case management of HMO patients, 1

Renal disease

as determinant of increased lipoprotein(a) concentrations, 2033

end-stage, improving prognosis in, B80 Renal function, high-dose vitamin E supplementation and, in type 1 diabetes, 1245

Renal insufficiency, incidence of, in type 1 diabetes, 743

Renal tubular function, and glycosuria-related urinary excretion of 1,5-anhydroglucitol, 863

Repaglinide

compared with glyburide, in treatment of type 2 diabetes, 463

and meal-related glycemic control in type 2 diabetes, 789 with metformin, effect on glycemic control in

type 2 diabetes, 119 Retinal blood flow, high-dose vitamin E

supplementation and, in type 1 diabetes,

Retinopathy, 640, 570

exogenous estrogen exposures and changes in, 1984

fasting and post-methionine levels of homocysteine in NIDDM, implications for, 125 multiple patient reminders in screening for,

752 plasma concentration of magnesium and

progression of, 864 in pregnancy, insulin lispro and, 1750, 2100,

2101 progression of after improved metabolic

progression of after improved metabolic control in type 2 diabetes, 1944 proliferative

ACE gene polymorphism and, in type 1 diabetes, 1530

insulin lispro and development of, during pregnancy, 874 and risk of blindness in Mexico, 1905

and risk of blindness in Mexico, 1905 risk of developing, 846

and racial differences among individuals with type 2 diabetes, 779

Risk, of diabetes in new diagnostic category of impaired fasting glucose, 1490 Risk assessment, autoantibody-based, 1796

Risk factors

in children, 189 in low-income Mexican-American children, 203

and screening for complications in HMO setting, 208 Rochester Diabetic Neuropathy Study, 1479 S

Scandinavian Simvastatin Survival Study, 1771 Schizophrenia, metformin and insulin therapy in patient with uncontrolled diabetes and, 1912

Screening

for complications in HMO setting, risk and protective factors associated with, 208 and diagnostic criteria, ADA, 367, 368 for gestational diabetes, 418, 653, 654 for impaired glucose tolerance, 1988 for retinopathy, multiple patient reminders

and, 752

for type 2 diabetes, S20 Seattle Diabetic Foot Study, 1036 Seattle Japanese-American Community Diabetes Study, 1808

Self-management education, third-party reimbursement for, \$105

Semmes-Weinstein monofilament sources of discrepancies in use of, 598 use of in Strong Heart Study, 1715

Sensorimotor polyneuropathy, specific fiber deficits in, correspond to cytotoxicity against neuroblastoma cells, 1839

Sex

of children with type 1 diabetes, microalbuminuria prevalence varies with, 495

relationship to fasting and postload glucose levels, 430

Sex hormone-binding globulin levels, in middle-aged premenopausal women, 1875

Simvastatin

and cardiovascular resource utilization in impaired fasting glucose and diabetes, 1771

does not reverse endothelial dysfunction in type 2 diabetic patients with hypercholesterolemia, 1224 drug interaction with troglitazone, 2104,

2105

Skaraborg Diabetes Registry, 773 Skin complications, in type 2 diabetes, association of G825 polymorphism in RAGE gene with, 1745

Smoking, 1887

and diabetes risk in elderly Finnish men, 1821

and increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients, 1871

and increased serum levels of TGF-β, 1915 Social environment, influence on type 1 diabetes risk in African-American and Latino children, 78

Soluble adhesion molecules, antioxidant effects of, in type 2 diabetes, 528, 529

Soluble intercellular adhesion molecule, as early marker of vasculopathy in type 2 diabetes without microalbuminuria, 1865 Soluble L-selectin, as marker for coronary

artery disease in type 2 diabetes, 2044 Stress, and glycemic control in type 1 diabetes, 1278

Stroke, nephropathy associated with increased familial risk of stroke, 422

Strong Heart Study, 1715, 1802

Sulfonylurea(s)

and exercise, and glucose homeostasis in type 2 diabetes, 1647 -induced low blood glucose, low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to, 2037 in type 2 diabetes, and homeostasis model

assessment as clinical index of insulin resistance, 818

Summary of Revisions for 1999 Clinical Practice Recommendations, S2

Supplies, third-party reimbursement for, \$105 Swedes, middle-aged male, low birth weight, glucose intolerance, and family history of diabetes in, 1043

Syndrome X, prevalence of, in parents of type 1 diabetic patients with or without nephropathy, 1048

Systolic blood pressure, and plasma triglycerides in diabetic peripheral arterial disease, 453

T

T-cell insulitis, found in anti-GAD65 diabetes with residual β-cell function, 615

Telecom Study, 1361

Testing, of glycemia, 577

Texas, revised standards for treatment of type 2 diabetes in, 1219

Therapeutic options, in type 2 diabetes, C76 Therapies, unproven, S104 Thiazolidinedione, effects on body fat and fat

distribution in type 2 diabetes, 288
Third-party reimbursement for diabetes care,

self-management education, and supplies, \$105

Thrifty gene, evidence in Paleoindian burial, 176

Thrombolyis, compared with primary angioplasty, in acute myocardial infarction, 647

Thyroid autoimmunity, clinical presentation and early course of type 1 diabetes in, 377

Transcutaneous near-infrared spectroscopy, to measure blood glucose during hypoglycemia, 2026

Transcutaneous oxygen tension, as predictor for outcome in foot ulcers, 147

Transferrrin excretion, increased urinary, as predictor of microalbuminuria in type 2 diabetes, 1176

Transforming growth factor-β, increased levels of, smoking and, 1915 Transplantation, kidney and pancreas, risks and

benefits of, B114

Treatment

antidiabetic treatment trends in elderly, 736 intensified, in type 1 diabetes, B29 satisfaction, calculating, 1760 of type 2 diabetes, 170

Tretinoin, and necrobiosis lipoidica diabeticorum, 1753

Triglycerides, plasma, in diabetic peripheral arterial disease, 453

Troglitazone

antihyperglycemic activity and role in treatment of type 2 diabetes, 1568 drug interaction with simvastatin, 2104,

2105

effect on body fat distribution, in type 2 diabetes, 908 effect on lipoprotein(a) levels, 859

in obese subjects, 1752 efficacy in subject with glucocorticoidinduced diabetes, 2088

and increase of HDL cholesterol levels, 355 liver dysfunction after 19 months of

treatment with, 1382, 1384

Tumor necrosis factor-α, and metabolic control in type 1 diabetes, 1749

Tumor necrosis factor receptor-1, insulin response to intravenous glucose correlates with plasma levels of, 868, 870

12-Item Well-Being Questionnaire, 2004 Type 1 diabetes, 1578

ACE gene polymorphism and proliferative retinopathy in, 1530

ACE inhibitors improve endothelial function in, 1536

in adolescents

glomerular hyperfiltration and ACE insertion/deletion polymorphism in, 618

leptin and, 1590

physical activity and competitive sports and, 1904

with poorly controlled, failure to maintain benefits of home-based intervention in, 1933

urinary excretion of albumin in, 1555 and young adults, increased Na/Licountertransport activity may help identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria, 1158

albuminuria in, increased small dense LDL and intermediate-density lipoprotein and 1165

augmentation of central arterial pressure in, 1722

blood glucose awareness training and epinephrine responses to hypoglycemia in, 1022

blunted erythropoietin response to anemia in, 647

bone mineral density in, 1196 characteristics and prognosis of

normoalbuminuric patients with, B72

childhood, perinatal and neonatal determinants of, 928

childhood-onset, neonatal anthropometric measurements and risk of, 2092 in children

conventional versus intensive therapy in, 1318

8 mm needles reduce risk of intramuscular injections in, 1621

glomerular hyperfiltration and ACE insertion/deletion polymorphism in, 618

leptin and, 1590

pen injectors versus insulin syringes in, 137

physical activity and competitive sports and, 1904

predictors of change in

neuropsychological profiles of, 1438 circadian blood pressure during early course of, 1151

clinical presentation and early course of, in patients with and without thyroid autoimmunity, 377

cotherapy with IGF-1 and insulin improves glycemic control in, 585

cyclosporine nephrotoxicity in, 478 durable reversal of hypoglycemia unawareness in, 866

effect of Bacillus Calmette-Guerin vaccine on new-onset, 1703 effect of moderate improvement in metabolic control on magnesium and lipid concentrations in, 546

enterovirus antibodies and islet cell antibodies in, 2086

in Europeans, fiber intake, serum cholesterol levels, and cardiovascular disease in. B21

in Filipinos, GAD65 antibodies and tyrosine phosphatase-like molecule IA-2ic in, 1458

genetics and prediction of complications in, B53

hepatocyte nuclear factor-1a

diabetes/MODY3 masquerading as, 867 high-dose vitamin E supplementation

normalizes retinal blood flow and creatinine clearance in, 1245 hyperglycemia, optimal administration of

lispro in, 133 hypersensitivity to regular and intermediate

insulin as aggravation factor for bulimia nervosa in, 1221

hypoglycemia associated with maprotiline in patient with, 862

immediate feedback of HbA1c levels and improved glycemic control in, 1785

impact of peripheral neuropathy on bone density in, 827

improved glycemic control reduces impact of weight gain on cardiovascular risk factors in, 1084

improving prognosis of, B1

incidence of renal insufficiency in, 743 influence of blood glucose self-monitoring on glycemic control in, 854

influence of glycemic control on zinc urinary excretion in, 362

intensified treatment and education of, B29 intensive and nonintensive treatment for hypoglycemia in, B43

long-term intensive treatment of, with lispro in variable combination with NPH insulin at mealtime, 468

in male offspring, previous maternal abortion, longer gestation, and younger maternal age decrease risk of, 1063

meal carbohydrate content effects on insulin requirements in, 667

metabolic control in, tumor necrosis factor-α and, 1749

new approaches to, 1899

newly progressing autoimmune, chronic complications in, 1347

nicotinamide in, B16

normoalbuminuric normotensive, changes in glomerular filtration rate, urinary albumin excretion rate, and blood pressure in, 1512

onset age of in Finnish children, 1066 oxidative stress and antioxidant supplementation in, 870, 871

in patients with celiac disease, no effect of gluten-free diet on metabolic control of, 1747

perinatal risk factors for childhood, 1698 on physiologic intensive therapy with lispro at mealtime, contribution of postprandial versus interprandial blood glucose to HbA1c in, 795

plastic insulin dosage guide to correct blood glucose levels out of target range and for carbohydrate counting in, 1252

pre-, primary and secondary prevention strategies of, B4

pregnancy, improving prognosis in, B104 in prepubertal children, counterregulation during spontaneous nocturnal hypoglycemia in, 1144

prevalence of syndrome X in parents of patients with, 1048

prevention, \$102

with residual B-cell function, cellular immune response to GAD in, 1758.

risk in African-American and Latino children, influence of social environment and year of birth on, 78

serum levels of AGEs associated with left ventricular diastolic function, 1186

severity of glomerulopathy predicts longterm urinary albumin excretion rate in patients with, 314

slow, crucial points at diagnosis, B59 stress and glycemic control in, 1278

in teenagers and young adults, eating habits, body weight, and insulin misuse in,

in very young children, clinical, autoimmune, and genetic characteristics

vitamin E supplementation and oxidative damage to DNA and plasma LDL in, 1626

Wegener's granulomatosis with pulmonary hemorrhage in boy with, 1591 Wolfram syndrome in, fundoscopy for

diagnosis of, 1376

in women

implanted insulin pump may represent chance to give birth for, 1001

red blood cell autoantibodies with shortened erythrocyte life span as cause of lack of relation between glycosylated hemoglobin and mean blood glucose levels in, 2085

in young patients correlation of fingerstick blood glucose measurements with results of GlucoWatch Biographer in, 1708

and intensive therapy for macrovascular disease, B35

smoking and increased plasma circulating intercellular adhesion molecule 1 levels in, 1871

Type 2 diabetes ACE gene polymorphism and arterial

stiffness in, 1858 and acute myocardial infarction, 1832

α-lipoic acid treatment, and decreased serum lactate and pyruvate concentrations and improved glucose effectiveness in lean and obese patients with, 280

aminotransferase activity and acarbose treatment in, 1217

antioxidant effects of gliclazide and soluble adhesion molecules in, 528, 529

in Asians, GAD antibodies in classification of, 1011

association between macronutrient intake and lipoprotein profile in, 1632

asymptomatic coronary artery disease associated with cardiac autonomic neuropathy and diabetic nephropathy in, 1745

blood lipid levels in, diet and, 1605

bone mineral density in, 1196 C282Y and H63D mutations of hemochromatosis candidate gene in.

cardiovascular disease in, 1739

cause-specific mortality in, 756 comparison of repaglinide and glyburide in treatment of, 463

continuous subcutaneous infusion of GLP-1 and lower plasma glucose, reduced appetite in, 1137

correlates of physical activity in sample of older adults with, 706

correlation between intima-media thickness of carotid artery and aortic pulse-wave velocity in, 1851

crucial points at diagnosis, B59 current therapeutic options in, C65

depression in, 997

early-onset autosomal-dominant, phenotypic characteristics unlinked to MODY genes,

effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in, 889

effect of troglitazone on body fat distribution in, 908

effects of hyperglycemia and improvement of glycemic control on macrovascular events in, C54

effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in, 1401

effects of thiazolidinedione on body fat and fat distribution in, 288

in elderly

clinical features of, 1225, 1226 low-dose ethanol predisposes to sulfonylurea-induced low blood glucose, 2037

elevated remnant-like lipoprotein particles in. 152

emerging epidemic of in youth, 345 excess maternal transmission of, 938 fasting and post-methionine levels of

homocysteine in, 125 fasting proinsulin concentrations predict

development of, 262 G825 polymorphism in RAGE gene and skin complications in, 1745

glucose control in, C57 glycemic control in, repaglinide with metformin and, 119

HDL cholesterol subfractions and risk of

developing among Pima Indians, 271 high normal blood pressure, hypertension,

and risk of, in Japanese men, 1683 with hypercholesterolemia, simvastatin does not reverse endothelial dysfunction in, 1224

hyperhomocysteinemia as risk factor for coronary arteriosclerosis in Japanese patients with, 484

hyperinsulinemia and development of, 86 hypertensive, ACE inhibitor-induced cough in, 1586

impaired diurnal cardiac autonomic function in, 2072

improving prognosis in, B84 incidence in Australian aboriginal population, 1993

increased intimal-medial thickness in newly detected, 333

increased urinary transferrin excretion as predictor of microalbuminuria in, 1176 incremental medical care costs during first 8 years after diagnosis, 1116

insulin sensitivity, 562

in African-American children with and without family history of, 1325

insulin therapy in, C65 and macrovascular risk factors in, C45

insulin-treated

immediate feedback of HbA1c levels and improved glycemic control in, 1785 and risk of foot ulcers, 1379

insulitis, in autoimmune-mediated patient originally classified as having, 541 interaction of sulfonylureas and exercise on

glucose homeostasis in, 1647 in Japanese men

alcohol consumption and risk of, 1432 depressive symptoms and occurrence of, 1071

Konjac-mannan improves glycemia and associated risk factors for coronary heart disease in, 913

lack of effect on LDL oxidation and antioxidant status after improvement in metabolic control in, 2083

in lean and obese subjects, proinsulin and  $\beta$ cell function in, 609

lispro Mix25 insulin as premeal therapy in, 459

liver disease in patients treated with oral antidiabetic agents, 2067

low-glycemic index diet for, improved glycemic control and lipid profile and normalized fibrinolytic activity and, 10

macrovascular disease in, C2 risk factors, C6

meal-related glycemic control by repaglinide and glyburide in, 789

metformin

added to insulin therapy in poorly controlled, 854 as adjuvant to insulin therapy in, 528

efficacy in treatment of, 33

microvascular dysfunction in non-glabrous skin of, 1549

in middle-aged and elderly obese patients, metabolic alterations and, 112 in the Netherlands, prevalence of deafness

increased in, 180

newly diagnosed, day-to-day variability fasting plasma glucose in, 394

non-insulin-using patients with, fasting plasma glucose as parameter of glycemic control in, 904

in nonobese Japanese, insulin-sensitive and insulin-resistant variants in, 2102

normocholesterolemic, apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in, 812

oral agent therapy in, C61, C65 oral antihyperglycemic agents and macrovascular risk factors in, C41

parasympathetic neuropathy in, obesity, microalbuminuria, hyperinsulinemia, and increased PAI-1 activity associated with, 1907

parental history of, and insulin sensitivity and glucose effectiveness in obese

nondiabetic offspring of African-American parents, 1594

pathogenesis of complications, 1209 in patients with different subtypes of ischemic stroke, insulin resistance and,

1191 pharmacologic induction of weight loss in,

prediction of cardiovascular events in highrisk, 19 prevalence of patients reaching target of good

control in, 2092 prevention, 623

progression of retinopathy after improved metabolic control in, 1944

and pseudohypoparathyroidism and obesity,

quality of life in, affected by complications but not by intensive policies to improve blood glucose or blood pressure control, 1125

racial difference among individuals with, and risk of retinopathy, 779

racial and ethnic differences in glycemic control in, 403

randomized trial of prepared meal program in, 191 reducing cardiovascular complications in,

1769 requiring insulin, insulin-sensitizing agents

and, 1004 revised standards for treatment of, in Texas, 1219

screening for, \$20

serum levels of AGEs increased in patients with coronary heart disease and, 1543

significant improvement in HbA1c in morbidly obese patient with, after gastric bypass, 651

soluble L-selectin as marker for coronary artery disease in, 2044

sustained improvement of glycemic control by insulin treatment after 9 years in patients with, 1373

therapeutic approaches to, C1 therapeutic options in, C76

total plasma homocysteine and insulin levels in, with secondary failure to oral agents, 2097

treated with sulfonylureas, and homeostasis model assessment as clinical index of insulin resistance, 818

treating obesity in, 886 treatment, 170, 357, 1209

trial of acarbose in shows improved glycemic control over 3 years, 960

troglitazone in treatment of, 1568 underdiagnosis of, using ADA criteria, 649 in urban African-Americans, overcoming clinical inertia improves glycemic control in, 1494

use of insulin therapy alone as pharmacological treatment for, C71 use of metformin for, in large HMO, 38 weight change and duration of overweight

and obesity in, 1266 weight loss in, treatment with acarbose and,

without microalbuminuria, soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity as early markers of vasculopathy in, 1865

without nephropathy, increased levels of serum pentosidine but not carboxymethyl lysine in, 877

in women

effect of walking on cardiovascular risk factors and body composition on, 555

exercise training and oxygen uptake kinetic response in, 1640

in young Chinese, and plasma insulin, growth hormone, cortisol, and central obesity, 1450

in young cocaine abuser, hyperglycemic hyperosmolar nonketotic syndrome, as initial presentation of, 1380

youth-onset, associated with HNF1A S319 in aboriginal Canadians, 2095

Tyrosine phosphatase-like molecule IA-2ic, and GAD65 antibodies, in Filipino type 1 diabetic patients, 1458

Undiagnosed diabetes predictive model to identify, 213 prevalence in U.S. Army population, 426 Prospective Diabetes Study, 960, 989,

1125

implications of, \$27 Unproven therapies, S104

Urinary albumin excretion

in adolescents with type 1 diabetes, 1555 and body composition and hyperinsulinemia in normotensive glucose-tolerant adults, 1728

rate

in normoalbuminuric normotensive type 1 diabetes, 1512

severity of glomerulopathy predicts, in patients with type 1 diabetes and microalbuminuria, 314

Urinary protein excretion, abnormality in, in Japanese men with impaired glucose tolerance, 823

Urinary transferrin excretion, increased, as predictor of microalbuminuria in type 2 diabetes, 1176

Urticaria, hypoglycemic, 861

Vascular cell adhesion molecule, as early marker of vasculopathy in type 2 diabetes without microalbuminuria, 1865 Vascular complications, inflammation and, 1927

Vascular disease, walking training for intermittent claudication, 198

Vascular factors, postmenopausal hormone replacement therapy and, 1401

Vascular surgery, and podiatry collaboration, and prevention of amputation, 679

Vasculopathy, soluble intercellular adhesion molecule, vascular cell adhesion molecule. and impaired microvascular reactivity as early markers of, in type 2 diabetes without microalbuminuria, 1865

Vasodilation, impaired endothelium-dependent, in type 2 diabetes, 973

Venlafaxine, in treatment of painful peripheral neuropathy, 1909 Verona Diabetes Study, 756

Visceral adipose tissue, age-related increase in, and metabolic risk profile of premenopausal women, 1471

Visceral adiposity, and incident coronary heart disease in Japanese-American men, 1808

Vitamin C, high-dose supplementation, and increased plasma glucose, 1218

Vitamin E

high-dose supplementation with, 1242 normalizes retinal blood flow and creatinine clearance in type 1 diabetes, 1245

supplementation, and oxidative damage to DNA and plasma LDL in type 1 diabetes, 1626

### W

Walking, effect on cardiovascular risk factors and body composition in normoglycemic women and women with type 2 diabetes, 555

Walking training, for intermittent claudication, 198

Wegener's granulomatosis, with pulmonary hemorrhage in boy with type 1 diabetes, 1591

Weight change, and duration of overweight and obesity in type 2 diabetes, 1266

Weight gain

early, and risk of type 1 diabetes, 1961 improved glycemic control reduces impact of, on cardiovascular risk factors in type 1 diabetes, 1084

Weight loss effect on plasma lipids and glucose in type 2 diabetes, 889

pharmacologic induction of, in type 2 diabetes, 896

spontaneous recovery of severe, in diabetic amyotrophy, 1906

in type 2 diabetic patient, acarbose and, 645 Werner's syndrome, impaired insulin secretion with concomitant insulin resistance, and development of overt diabetes in, 2094 West African-origin populations, glucose intolerance in, 434

Wisconsin Epidemiologic Study of Diabetic Retinopathy, 951, 1984

Wolfram syndrome

fundoscopy for diagnosis of, 1376 partial, 1376

Women

consequences of new diagnostic criteria in older, 1667

diabetic pregnant, folate deficiency and, 1017

education and metabolic syndrome and, 1999

with gestational diabetes birth weight of, 1059

more likely to have been bottle-fed?, 1747 middle-aged premenopausal, sex hormone-

binding globulin levels in, 1875 mortality and hormone-related exposures in, 248

normoglycemic, effect of walking on cardiovascular risk factors and body composition in, 555

with polycystic ovary syndrome, prevalence of impaired glucose tolerance in, 141

postmenopausal, muscle fiber characteristics in, 1330

preconception care of, S62 pregnant, with type 1 diabetes, ambulatory blood pressure monitoring of, 1507

premenopausal, age-related increase in visceral adipose tissue and body fat and metabolic risk profile of, 1471 with previous gestational diabetes

early postpartum metabolic assessment in,

new diagnostic criteria for abnormal glucose homeostasis in, 933 screening for gestational diabetes, 535 with type 1 diabetes, red blood cell autoantibodies with shortened erythrocyte life span as cause of lack of relation between glycosylated hemoglobin and mean blood glucose levels in, 2085

with type 2 diabetes

effect of walking on cardiovascular risk factors and body composition in, 555

exercise training and oxygen uptake kinetic response in, 1640

with unstable type 1 diabetes, implanted insulin pump may represent chance to give birth for, 1001

Work disability, and diabetes, 1105 Work environment, impact on glycemic control, 569

World Health Organization

criteria, concordance with ADA 1997 criteria in Northern Italian population, 652

diagnostic criteria, compared with ADA diagnostic criteria, 1755, 1756 fasting criteria, concordance with ADA 1997 fasting criteria in Mexican subjects, 527

# Y

Youth

emerging epidemic of type 2 diabetes in, 345 minority, risk for metabolic control problems in, 700

Pima Indian, birth weight, type 2 diabetes, and insulin resistance in, 944

with type 1 diabetes, increased Na/Licountertransport activity may help those at risk for developing persistent microalbuminuria, 1158

# 7

Zinc, urinary excretion of, glycemic control and, 362

# **Author Index**

Page numbers with prefix B are found in Supplement 2 (March). Page numbers with prefix C are found in Supplement 3 (April).

Aaser, E., 45 Abbott, R.D., 1262 Abe, R., 1754 Abe, T., 366 Abou-Amara, S., 388 Abraham, M.R., 1380, 1916 Abrahamian, H., 1530 Ackerman, N.R., 1708 Ackerson, L.M., 938 Adèr, H.J., 2004 Adler, A.I., 543, 1029 Aguayo, F.C.C., 1905 Aguilera, E., 1507 Aharon, Y., 2026 Ahmed, K., 394 Ahrén, B., 1330, 1913 Ahroni, J.H., 965, 1029, 1036 Aiello, L.M., 1245 Aiello, L.P., 1245 Aizawa, T., 1584 Åkerblom, H.K., 1950, 1961 Akhter, J., 320 Al-Sharafi, B.A., 1916 ALADIN III Study Group, 1296 Albareda, M., 371 Alberti, K.G.M.M., 399 Albertini, J.-P., 2044 Alberto, M., 1379 Albright, A., 208 Alex, D., 328 Alexander, C.M., 1771 Ali, S., 491 Alibrandi, A., 1591 Allen, H.F., 1009, 1703 Almgren, P., 1347 Altman, J.-J., 2089 Altura, B.M., 546 Altura, B.T., 546 Alvarsson, M., 1043 Ambergen, A.W., 1749 Ambrosioni, E., 1586 American Diabetes Association, 163, 167, 1354 Amiel, S.A., 1607 Anderson, B.J., 713, 832 Anderson, C.M., 2095 Anderson, G.F., 1660 Anderson, L., 661 Anderson, P.J., 1438 Anderson, R.M., 2090 Andersson, A., B121 Andreassen, H., 827 Andrewes, D., 1438 Angelkort, B., 674 Anhalt, H., 651 Antonella, Q., 1379 Applegate, E.B., 700 Aquilino, C., 569 Arcari, R., 50 Arcaro, G., 1536 ARIC Study Investigators, 1077

Arnqvist, H.J., 409

Arslanian, S.A., 1325

Arora, V., 1258

Asazuma, K., 484

ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association), B29
Asp, N.-G.L., 10
Asplund, K., 1988
Assadkhani, A., 280
Astley, S., 1626
Atkinson, A.B., 2061
Atsumi, Y., 615
Attali, J.-R., 2044
Aubert, R.E., 1
Austin, E.J., 1273
Azar, S.T., 1372, 1376
Azarya, M., 328

Baan, C.A., 213 Baba, T., 1376 Babaya, N., 863 Babyak, L.M., 1549 Bache, I., 1063 Baer, R.D., 722 Baiget, M., 525 Bajaj, M., 1022 Baker, G., 202 Baker, L., 585 Bakker, A.J., 307, 1600 Bakst, A.W., 1116 Balasekaran, G., 1325 Bald, E., 2097 Balkau, B., 434, 696, 1361, 1385 Bangar, S.S., 366 Bangstad, H.-J., 314 Bantle, J.P., 896 Baranyi, É., 870 Barba, E.J.R., 1905 Bardini, G., 368 Barnes, R.B., 141 Barnett, A.H., 1278 Baron, A.D., 883, 1310 Barriga, K.J., 1694 Bartocci, L., 468 Barzilay, J., 1011 Barzilay, J.I., 736 Bastyr, E.J., III, 1422 Bauer, T.A., 1640 Baz, P., 1376 Bazzigaluppi, E., 275 Bean, J.A., 1092 Beck, M.O., 1745 Beck-Nielsen, H., 546 Becker, D., 1084 Becker, H.D., 294 Beerdsen, P., 1501 Bejjani, R., 1376 Belarbi, N., 1621 Belch, J.J.F., 528 Belicar, P., 1001 Belicar, P., 2089 Bell, D.S.H., 859, 1000, 1921 Bell, G.I., 867 Belman, M.J., 208 Ben-Ami, H., 860 Benhaddad, A.A., 1003 Benhamou, P.Y., 19 Benjamin, E.M., 1672 Bennett, F., 434

Bennett, P.H., 413, 944

Berg, T.J., 314, 1186, 1543 Berger, B., 773

Berden, J.H., 1048

Berger, M., B29, C71

Bergeron, J., 1471 Bergholm, R., 973 Berglund, L., 93 Bergstrom, R.W., 1808 Berlin, J.A., 692 Bernard, A.M., 661 Berne, C., 93 Berntorp, E., 1944 Berntorp, K., 1907, 1944 Berry, M., 339 Bertoncello, N., 1590 Bertrais, S., 696 Bethel, M.A., C61 Bhalwar, R., 366 Bhargava, N., 1318 Bhattacharyya, A., 2101 Bienvenu, B., 1584 Bierhaus, A., 1227 Binder, C., 609 Bingley, P.J., 275, 1796, 2049 Birkeland, K.I., 1543 Bittner, V.A., 736 Björck, I.E., 10 Bjørndal, A., 1813 Bjørnholt, J.V, 45, 1386 Blaabjerg, O., 546 Blachowicz, J., 854 Black, S.A., 56 Blohmé, G., 409 Blonde, L., 1004 Bloomgarden, Z.T, 170, 357, 517, 640, 849, 989, 1209, 1364, 1578, 1739, 1899, 2078 Blough, D., 382 Blum, W.F., 1097 Bo, S., 2092 Boccuzzi, S.J., 1771 Bock, T., 1063 Bodansky, H.J., 928 Boemi, M., 2033 Boer, J.M.A., 1919 Böhles, H.J., 280 Boivin, S., 1001, 2089 Boland, E.A., 1779 Bolinder, J., 409 Bolli, G.B., B43, 468, 795 Boman, J.E., 364 Bonadonna, R., 1339 Bonadonna, R.C., 1536 Bonet, R., 812 Bonfanti, R., 275 Bonifacio, E., 275 Bonnemaire, M., 2089 Bonora, E., 756, 1339 Boomsma, L.J., 180 Borch-Johnsen, K., B1 Bornmyr, S., 593 Borra, M., 50 Bortolotti, N., 2084 Bory, M., 1396 Bosi, E., 275 Bosnyák, Z., 876 Bottazzo, G.F., 2049 Bouchard, C., 1471 Bouhanick, B., 618 Boulton, A.J., 1839 Boulton, A.J.M., 157, 1428 Bouma, M., 904 Bourguignon, J.-P., 1845 Bouter, L.M., 1097 Bowsher, R.R., 1422 Boyages, S., 119 Boyd, A.S., 1753

Boyko, E.J., 65, 157, 762, 965, 1029, 1036, 1808

#### AUTHOR INDEX 1999

Boyne, M.S., C45 Brackett, J., 713 Bradley, C., 530, 1759 Brancati, F.L., 1408 Branch, D.R., 1218 Branchi, A., 372 Brandenburg, S.L., 1640 Brazy, P.C., 743 Bretzel, R., 1832 Brighenti, F., 913 Brill, H.-L., 674 Bringer, J., 1371 Brinton, E.A., 678 Brismar, K., 147 Broch, M., 868 Brooks, B., 1722 Brown, J.B., 38, 1011, 1116 Brown, M.B., 418 Bruce-Thompson, C., 913 Brun, J.-F., 1003 Brunetti, P., 468, 795 Bruno, A., 652 Bruno, G., 50 Brunzell, J.D., C10, 1165 Bryden, K.S., 1956 Buchanan, T.A., 535 Buithieu, M., 1592 Bulmer, K., 363 Burak, W., 1387 Burchfiel, C.M., 1262 Burcus, N., 1839 Burge, M.R., 133, 2037 Burkart, V., B16 Burke, J.P., 1655 Bursell, S.-E., 1245 Burtner, C., 1310 Buschard, K., 1063 Buse, J.B., C65 Bush, A.J., 1524 Bussell, K., 426 Bussell, N., 426 Butler-Jones, D., 925 Butte, N.F., 806 Buyken, A.E., B21 Byrne, C.D., 262

Caballero, A.E., 1865 Cacciatori, V., 1871 Cagliero, E., 1785 Calmar, S., 2089 Calvo, F., 812 Campbell, L.V., 1401 Campistol, J.M., 1915 Campos, R.V., 603 Canadian Lispro Study Group, 603 Cao, H., 524 Capeau, J., 1374 Caputo, S., 647 Caramori, M.L.A., 1512 Carlsson, S., 1043 Carpenter, S., 1252 Carrascosa, A., 871 Carroll, T.A., 495 Carson, M.N., 453 Carta, Q., 50 Cartechini, M.G., 468 Carter, J., 119 Casamitjana, R., 868 Cases, A., 1915 Casey, E., 998

Casper, M.L., 441

Castello, E., 1612

Castellví, A., 812 Castelnuovo, P., 1591 Castenfors, J., 593, 1907 Catino, M., 1158 Catone, B., 2084 Cattalini, N., 176 Cavaghan, M.K., 141 Cavallo-Perin, P., 2092 CDC Diabetes in Managed Care Work Group, 1734 Ceriello, A., 1384, 2084 Cernigoi, A.M., 1755 Cerutti, C., 388 Cerutti, F., 1587 Cesarini, P.R., 362 Chait, A., 191 Chambless, L.E., 1077 Chan, C.H.S., 1751 Chan, J.C.N., 1450, 1908, 2096 Chan, N.N., 178, 370 Chang, C.-J., 861, 1938 Chapin, B.L., 426 Chase, H.P., 1703, 1708 Chatterjee, S., 1226 Chaturvedi, N., 430 Chen, K.-W., 1808 Chen, R., 1751 Chen, Y.-T., 1224 Chen-Daniel, J., 867 Cheng, A.Y., 1216 Chessler, S.D., 65 Cheung, A.Y.K., 2096 Chiang, C.-H., 861 Chiara, D.L., 795 Chiarelli, F., 7, 1158 Chiari, G., 7 Chiasson, J.-L., 667 Childhood Diabetes in Finland (DiMe) Study Group, 1950, 1961, 2092 Chin. D., 651 Chiou, S.-H., 861 Chitson, P., 399 Chiu, N.-T., 1938 Choi, H., 78 Chou, C.-K., 861 Chou, P., 370 Chow, C.-C., 1450, 2096 Chwatko, G., 2097 Ciavarella, A., 1586 Ciofetta, M., 468, 795 Claria, J., 1915 Clark, C.M., Jr., C1, C79 Clark, D.O., 706 Clark, S., 191 Clark, W.S., 1517 Clarke, W.L., 580, 2018 Classen, D.C., 1760 Classen, J.B., 1760 Claudi, T., 1813 Clausell, N., 1745 Clauson, P., 789 Claussen, C., 294 Cleary, P.A., 1165 Clermont, A.C., 1245 Clifton, P.M., 889 Cobelli, C., 280 Cocciolo, M., 176 Cockburn, B.N., 867 Cockram, C.S., 369, 1450, 1908, 2096 Coerper, S., 294

Coleman, K.J., 1747 Colli, A., 176 Collier, G., 1092 Collin, P., 1747 Colwell, J.A., 1927 Compagnucci, P., 468 Compton, P.G., 585 Cook, C.B., 369, 661, 1415, 1494 Cook, J.R., 1771 Cooper, L.S., 1077 Corcoy, R., 370, 2099 Cordonnier, D., 19 Costa, M., 2011 Costalat, G., 1371 Costi, G., 7 Cotroneo, P., 647 Couillard, C., 1471 Couper, J.J., 1933 Coutinho, M., 233 Cowie, C.C., 403 Cox, D.J., 580, 832, 1022, 2018 Cozzolino, S.M.F., 362 Craft, S., 1318 Critchley, J.A.J.H., 1450 Croft, J.B., 441 Cronin, J., 1310 Crowne, E.C., 1144 Cruickshanks, K.J., 743 Cryer, P.E., 866 Cseh, K., 870 Cucuianu, M., 1381 Cull, C.A., 960 Cundy, T., 653 Curb, J.D., 1262 Curfs, D.M.J., 1749 Czernichow, P., 1621

Czupryniak, L., 2097 D'Agostino, R., Jr., 562, 1688 d'Annunzio, G., 1591 Dabelea, D., 944 Dagogo-Jack, S., 866 Dahlén, G., 93 Dahlquist, G.G., B4, 365, 1698 Daimon, M., 877 Dalton, N., 495 Damiani, P., 647 Damsbo, P., 789 Danadian, K., 1325 Daniel, M., 1993 Daniels, J.E., 1278 Dargis, V., 1428 Darko, D., 178, 370 Daugaard, J.R., 1330 Davey, R., 873 Davidson, J., 1219 Davidson, M.B., 1487 Davies, J.L., 1479 Davignon, D.R., 1036 Davis, J.L., 1909 Davis, W.S., 535, 653, 874, 1747 Day, N.E., 262 de Azevedo, M.J., 1512, 1599 De Bellis, A., 1755 de Boer, M.-J., 647 De Casson, F.B., 618 de Courten, M., 399, 762, 1092 de Marco, R., 756 de Martino, M., 1158 de Pergola, G., B21 De Salvia, A., 50 de Sonnaville, J.J., 904

Cogswell, M.E., 1978

Cohen, R.D., 1010

Colagiuri, S., 119

De Stefano, A.M., 1590 de Swiet, M., 933 de Valk, H.W., 864 de Vries, H., 904 Deary, I.J., 1273 Deb, P., 1105 DeCarlo Donahue, R., 1092 **DECODE Study Group, 1667** DeFronzo, R.A., 1462 Deichmann, R.E., 1612 Dekker, J.H., 904 Dekker, J.M., 213, 1097 del Aguila, M., 157 Del Sindaco, P., 468, 795 Dela, E., 1647 Delamater, A.M., 700 Dellon, A.L., 1914 DeMacker, P.N.M., 371, 1752 Denis, B., 19 Derkenne, B., 1845 Desbois-Mouthon, C., 1374 Després, J.-P., C38, 1471 Devarajoo, S., 1597 Diabetes Prevention Program, 623 DIAINF Study Group, 1755 Dinesen, B., 609 Djurhuus, M.S., 546 Dobs, A.S., 736 Doi, K., 1911, 2100 Domínguez, C., 871 Donahue, R.P., 1092 Donnelly, T., 119 Donner, T.W., 2018 Doria, A., 253 Dornhorst, A., 933 Dost, A., 1904 Dowse, G.K., 399 DPP Research Group, 1757 Dreyfus, J., 253 Drum, M., 78 Drzewoski, J., 2097 du Pasquier-Fediaevsky, L., 1445, 1621 Ducher, M., 388, 1388 Ducimetiere, P., 696 Dunbar, V., 1617 Dunbar, V.G., 1415, 1494 Duncan, B.B., 767 Dunger, D.B., 27, 495, 1144, 1956 Dunstan, F.D., 394 Dutch and German Repaglinide Study Group, 463 Dyck, P.J., 1479 Dyer, P.H., 1278 Eastman, R.C., 403

Ebbehøj, E., B72 Ebeling, P., 459 Eberhardt, M.S., 403 Eckel, R.H., C21 Edelman, S.V., 532 Edge, J.A., 27 Edmonds, M.E., 1966 Edoute, Y., 860 Edwards, A., 1750 Efendic, S., 1043 Egger, G., 1339 Eguchi, H., 877, 920 Eguchi, K., 484 Ehrmann, D.A., 141 Eidson, M., 700 Eisenbarth, G.S., B7, 1694

El-Kebbi, I.M., 1415, 1494, 1617

Elhadd, T.A., 528 Elian, N., 2089 Elliott, T., 112 Elving, L.D., 1048 Emmanuel, S.C., 241 Emoto, M., 818, 1851, 1858 Enderle, M.D., 294 Endo, G., 228, 1432, 1683 England, B.G., 1017 Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, 99 Epstein, M., 982 Erbey, J.R., 1084 Erickson, J.M., 320 Erikssen, G., 45 Erikssen, J., 45, 1386 Eriksson, J.W., 409 Erkelens, D.W., 864 Ernould, C., 1845 Ernst. K.L., 1494 Eschwege, E., 696, 1361, 1385 Escudero, M., 1378 Eskildsen, P., 827 Esmatjes, E., 1507, 1915 Esparza, J., 413 Ettinger, B., 38 EURODIAB IDDM Complications Study Group, B21 EVADIAC Group, 2089

Evans, A., 998 Ezio, E, 1379

Faber, J., 1186 Fabrizio, E, 1379 Fagot-Campagna, A., 271 Fagrell, B., 147 Fagret, D., 19 Fairburn, C.G., 1956 Falkner, B., 71 Fanelli, C.G., 866 Fareed, D., 399 Fauvel, J.P., 388, 1388 Feener, E.P., 1245 Feher, M.D., 856 Feinglos, M.N., C61 Feingold, K.R., 300, 1385 Feldman, S., 2089 Femerling, M., B29 Fermi, S.J., 1708 Fernández-Castañer, M., 377 Fernandez-Real, J.-M., 525, 868 Fernando, G.-R., 527 Fernlund, P., 1907, 1944 Ferrara, A., 938 Ferreira, S.R.G., 362 Ferry, T.G., 857 Feskens, E.J.M., 213, 1919 Finnish Childhood Diabetes Registry Group, 1066

Fisher, E.B., 832 Fiumi, N., 1586 Flegal, K.M., 403, 1605 Fliser, D., B80 Flores, L., 1507, 1915 Folsom, A.R., 1077 Fontaine, P., 1374 Ford, E.S., 1971, 1978 Forhan, A., 434 Fornengo, P., 652 Forrester, T., 434 Forsberg, R.C., 965, 1036

Forsen, T., 2092 Foster, A., 1966 Fotheringham, M.J., 1933 Fowkes, F.G.R., 453 Fox, C., 413 Francobandiera, G., 176 Fredrickson, L., 1779 Friday, K.E., 1612 Friedman, E.A., B65 Friedman, R., 1745 Frisbie, K., 320 Fujibayashi, K., 2088 Fujii, S., 228, 1432, 1683 Fujimoto, W.Y., 65, 1808 Fujinuma, H., 1754 Fujisawa, T., 863 Fujishima, M., 1382 Fujita, H., 823 Fujiwara, K., 1221 Fukui, M., 1011, 1225, 1758 Fukushima, M., 1911, 2100 Fuller, J.H., B21 Fumelli, P., 2033 Funae, O., 615, 1759 Funase, Y., 1584

Gabriely, I., 2026 Gaillard, T., 1588, 1594 Galbo, H., 1647 Gale, E.A.M., 495, 1796, 2049 Gallen, I.W., 1226 Gallina, D.L., 1415, 1494, 1617 Gallois, Y., 618 Gappmayer, B., 1882 Garcia de Alba Garcia, J.E., 722 Garcia-Ingelmo, T., 1053 Gardner, S.G., 2049 Gareeboo, H., 399 Garg, S.K., 1708 Garon, J., 667 Garvey, W.T., 1310 Gatta, B., 1002 Gattegno, L., 2044 Gaur, L.K., 1517 Gay, V., 1587 Genda, A., 355 Gentile, L., 2092 Gentile, S., 1217 Georgopoulos, A., 779 Gerstein, H.C., B35, 233, 659 Ghirlanda, G., 647 Ghizzoni, L., 7 Giacalone, T., 7 Gibert-Boulet, F., 1371 Gillespie, K.M., 2049 Gimferrer, E., 525 Gin, H., 1002 Giorgini, A., 1458 Giorgino, F., B21 Glasgow, R., 1887 Glasgow, R.E., 832, 2090 Glauber, H.S., 1116 Glazer, M., 722 Glick, H.A., 1110 Gniuli, D., 367 Goldberg, R.B., 1092 Golden, S.H., 1408 Goldstein, B.J., 532 Gomez, J., 202 Gómez, J.M., 377 Gomez, M., 1378

Gomis, R., 1507

Gonder-Frederick, L., 580 Gonder-Frederick, L.A., 2018 Gonzalez, A., 1053 Gonzalez-Mendoza, L., 700 Gorson, D.M., 1007 Gottsäter, A., 1913 Grabert, M., 1555 Granado Lorencio, F., 870 Grande, C., 1053, 2085 Granfeldt, Y.E., 10 Grassi, G., 652 Graves, P.M., 1694 Greco, A.V., 367 Greenlund, K.J., 441 Grenfell, A., 933 Grey, M., 1779 Grill, V., 1043 Groop, L., 1347 Groop, P.-H., 2055 Gross, J.L., 1512, 1599, 1745 Gross, P., 1001 Grosso, N., 50 Grzeszczak, W., 1387 Guarino, G., 1217 Gudat, U., 865 Guerriero, A., 1871 Gumbiner, B., 886 Gunczler, P., 1012 Gunton, J.E., 177 Gurney, K.A., 928 Gussinyé, M., 871 Gustin, M.P., 388 Guthrie, R.D., Jr, 1004 Gutiérrez, C., 868 Gutierrez, M., 1422

H

Haberbosch, W., 1832 Habib, G., 1396 Hadden, D.R., B104 Hadjadj, S., 618 Haffner, S.M., C54, 562, 1688 Hagopian, W., 409 Hagopian, W.A., 1517 Haire-Joshu, D., 1887 Hájek, D., 1745 Halabi, G., 1376 Halbert, R.J., 752 Hale, D.E., 202, 1655 Hales, C.N., 262, 1688 Half, E., 524 Halimi, S., 19 Hallmans, G., 1988 Halvorson, M., 1252 Hammoud, T., 19 Han, T.S., 288 Hanefeld, M., 333, 1296 Hanley, A.J.G., 524, 1216, 2095 Hänninen, J.A., 997 Hansen, K.W., B72 Hanson, R.L., 271, 944 Hanssen, K.F., 314, 1186, 1543 Harding, P.E., 503 Hardman, D.A., 300 Hardus, P.L.L.J., 864 Hardy, K.J., 422 Haring, H.U., 294 Harris, D.A., 27 Harris, E.L., 779 Harris, M.I., 403, 1679 Harris, N.D., 1292 Harris, S.B., 524, 2095

Harris, T., 1278

Harrower, A., 1227 Harrower, A.D.B., 1227 Hartling, S.G., 609 Hartmann, A., 314 Harvey, J.N., 1597 Harzer, O., 784 Hasche, H., 1296 Hashizume, K., 1584 Hassan, M., 1621 Hathout, E.H., 867 Hatton, D.C., 191 Hau, C.M., 451 Havel, P.J., 1144 Hawa, M.I., 1458 Hayakawa, M., 1176 Hayakawa, T., 366, 1220 Hayashi, T., 228, 1432, 1683 Haynes, R.B., 191 Hays, L.M., 706 Hayward, A., 1703 Hayward, C.S., 1401 Hazuda, H.P., 1655 Heckbert, S.R., 736 Hegele, R.A., 522, 2095 Heilbronn, L.K., 889 Heine, R.J., 213, 904, 1097, 2004 Heinemann, L., 865 Heinze, E., 1151, 1555 Heise, T., 865 Heiss, G., 767, 1077 Heitkamp, G., B21 Heller, S.R., 1607 Hellerström, C., B121 Hemraj, F., 399 Henderson, J.A., 1802 Heng, L.F., 598 Henkel, E., 333 Henley, S.A., 320 Henricsson, M., 1347, 1907, 1944 Henriksen, J.E., 546 Henry, R., 532 Henry, R.R., 1501 Herlitz, J., B89 Herman, W.H., 1, 418, 729, 1017, 1771 Hermann, K.M., 1530 Hernandez-Mijares, A., 1378 Herold, M., 1748 Herranz, L., 1053, 2085 Hershey, T., 1318 Herson, M.K., 1011 Hiatt, W.R., 1640 Hiddessen, A., 1832 Hildebrandt, P., 1186 Hinchey, K.T., 1672 Hirahashi, T., 1382 Hirano, R., 1754 Hirata, A., 877 Hirsch, I.B., 854 Hiura, Y., 818 Ho, J., 713 Hoffman, M.R., 1694 Höflich, A., 280 Hokanson, J.E., C10, 1165 Holl, R.W., 1151, 1555 Holman, R.R., 960 Holmen, J., 1813 Holst, J.J., 1137 Holstein, P.E., B97 Hood, K., 1597 Hook, G., 1310

Hoorntje, J.C.A., 647

Hopkins, D., 998

Hopkins, H., 119 Hoppichler, E, 1748 Hori, M., 2072 Horikoshi, H., 908 Horowitz, M., 339, 503 Horsten, M., 1999 Horswell, R., 1612 Horton, E.S., 1865 Hoshino, T., 1754 Hosoi, M., 1858 Houssa, P., 609 Howard, B., 562 Howard, B.V., 271, 1688, 1715, 1802 Howard, G., 1077 Hozumi, T., 1176 Hsiao, P.-J., 1181 Hsu, H.W., 806 Hsu, W.-M., 861 Hu, D., 1715, 1802 Hudson, R., 684 Hugo, K., 1422 Humalog Mix25 Study Group, 1258 Hunkert, F., 1008, 1904 Hyōty, H., 2086 Hypponen, E., 1961

Igarashi, K., 920 Igarashi, M., 877 Ikeda, Y., 908, 1176, 1917 Ikegami, H., 863, 2094 Ilic, S., 1422 llonen, J., 1950 Imazu, Y., 615 Imperatore, G., 944, 1490 Imperial, J., 141 Impivaara, O., 1196 Imseis, R.E., 1524 Iñigo, P., 1915 Iovino, V., 1490 lqbal, S., 418, 1017 Irsigler, K., 1530 Irwin, L.S., 1561 Isaacs, S.D., 1517 Isermann, B., 1227 Ishibashi, H., 1071 Ishida, Y., 1176 Ishikawa, S., 523, 2088 Ishikawa, Y., 152 Isomaa, B., 1347 Isotani, H., 862 Itabashi, N., 2088 Itakura, M., 1376 Ito, M.K., 2104 Ito, S., 823 Itoh, M., 1221 Itoh, Y., 1221 Iwamoto, Y., 1590 Iwasaki, M., 2072 Iwase, M., 1382

Jaap, A.J., 422 Jablonski, K.A., 1790, 1802 Jack, H., 1227 Jackson, R., 1171 Jacobson, A.M., 1022 Jacques-Apostol, D., 1371 Jaffiol, C., 1371 Jain, S.K., 1171, 1242 James, R.W., 2033 Janand-Delenne, B., 1396 Jañez, M., 1053, 2085 Jansen, H., 2083 Janssen, 1., 684 Jarrett, R.J., 1385 Jarvi. A.E., 10 Javorski, W.C., 2011 Jeandidier, N., 1001 Jeffers, B.W., 1640 Jenkins, D.J.A., 913 Jennings, P.E., 528 Jensen, M.D., 1728 Jensen, P., 1703 Jervell, J., 45, 1386 Jick, S.S., 2067 Joe, J.R., 345 Johansen, K., 33 Johnson, A., 1310 Johnson, S.B., 832 Johnston, D.G., 933 Johnston, G.D., 2061 Jones, J.A., 555 Jones, K.L., 339, 503 Jonushaite, A., 1428 Jörgens, V., B29, C71 Jörneskog, G., 147 Josse, R., 913 Jovanovic, L., 846, 1422 Joyce, M., 1501 Jóźwicka, E., 854 Juang, B.-L., 1224 Julian, D., 580 Julian, D.M., 2018 Juto, P., 364

Kahn, R., 1756 Kaider, A., 1530 Kakizawa, H., 1221 Kakou, B., 1621 Kalani, M., 147 Kameoka, K., 862 Kan, E.C.Y., 1751 Kanaan, N., 1372 Kanda, H., 818, 1851 Kangas, T., 575 Kantor, J., 692 Kao, W.H.L., 1408 Kapellen, T., 1904 Kaplan, J., 2026 Kaplan, J.S., 1017 Karibe, S., 1590 Karlström, B.E., 10 Karter, A.J., 938 Kartnig, I., 1882 Karvonen, M., 1066, 2092 Kasuga, A., 615, 1759, 1910 Katakura, M., 1584 Kataoka, K., 1376, 2100 Kato, S., 1221 Kato, T., 877, 920 Katoh, J., 1917 Kaufman, ER., 1252 Kaukinen, K., 1747 Kawabata, Y., 863 Kawagishi, T., 818, 1851, 1858 Kawaguchi, A., 1917 Kawaguchi, Y., 863 Kawakami, A., 523, 2088 Kawakami, N., 1071 Kawasaki, E., 541 Kazumi, T., 1176, 1917 Kanková, K., 1745 Keinänen-Kiukaanniemi, S.M., 997

Kekalainen, P., 86 Kelly, I.E., 288 Kelly, R.P., 1401 Kennedy Cruickshank, J., 434 Kenward, M.G., 1961 Kerényi, Z., 533, 876 Kerum, G., 1296 Khan, N., 651 Khardori, R., 1380, 1916 Khateeb, N.I., 651 Khoury, J., 806 Kiayias, J.A., 859 Kidson, W., 119 Kiechl, S., 1339 Kieffer, E.C., 729 Kiener, H.P., 1530 Kiens, B., 1330 Kiess, W., 1008, 1904 Kikuchi, H., 1754 Kilhovd, B.K., 1543 King, A., B121 King, G.L., C31, 1245 Kinsley, B.T., 1022 Kishi, K., 1176, 1917 Kishimoto, M., 2072 Kitabchi, A.E., 1517, 1524 Kitagawa, Y., 152 Kitzmiller, J.L., 874, 2102 Kjekshus, J., 1771 Klein, B.E.K., 248, 743, 951, 1984 Klein, R., 248, 743, 951, 1984 Klein, R.E., 722 Kleinjans, J.C.S., 1749 Klingensmith, G.J., 1703 Klitgaard, N.A.H., 546 Knights, S., 1059, 1747 Knip, M., 1950, 1961, 2086 Knowler, W.C., 271, 944, 1756 Ko, G.T.C., 1450, 1751, 1908, 2096 Kobayashi, K.I., 1004 Kobayashi, T., 1221 Koch, M., B80 Koch, T., 1748 Kodama, M., 2072 Koehler, C., 333 Kogawa, K., 1858 Kohen-Raz, A., 328 Kohen-Raz, R., 328 Koivisto, A.-M., 1747 Koivisto, V.A., 459, 575 Kolb, H., B16 Komatsu, M., 1584 Komulainen, J., 1950 Kondo, M., 1011, 1225, 1758 Kong, M., 503 Kong, M.-F., 339 Konopelska-Bahu, T., 495 Konrad, T., 280 Kopp, A.F., 294 Kosaka, S., 484 Kostense, P.J., 904, 1097 Kousta, E., 933 Kovatchev, B., 580 Kovatchev, B.P., 2018 Kraemer, F.B., 1302 Krentz, A., 998 Kriegsman, D.M., 904 Kris-Etherton, P., 191 Krivoy, N., 860 Krolewski, A.S., 253 Kromhout, D., 1919 Krop, J.S., 1660

Krüger, Ø., 1813

Krzymień, J., 854 Kulmala, P., 1950 Kulseng, B., B121 Kuntze, J.E., 585 Kurimoto, Y., 152 Kusaka, I., 523, 2088 Kushner, H., 71 Kusterer, K., 280 Kwiatek, M.A., 339 Kwong, C.A., 896

Laakso, M., 86 Ladyżyński, P., 854 Laffel, L., 1245 Laffel, L.M.B., 713 LaGreca, A., 832 Lahdenperä, S., 973 Lahtela, J., 1747 Lakatos, P., 870 Lalli, C., 468, 795 Lancashire, R.J., 1278 Lancelotta, G.X., 700 Landgraf, R., 463, 784 Landin-Olsson, M., 409 Lanes, R., 1012 Langelier, H., 667 Langrish-Smith, A., 1626 Lario, S., 1915 Larsen, J.J., 1647 Larsen, J.L., 320 Larsson, H., 1330 Lassmann-Vague, V., 1001, 1396 Latare, P., 1011 Lau, M.S.W., 1450 Lau, N., 1262 Lauton, D., 1371 Lavery, L.A., 157 Laville, M., 388 Law, G.R., 928 Lawrence, K.E., 2049 Lawrence, N.J., 933 Lawrenson, R.A., 856 Lawson, M.L., B35 Le, D., 426 Leaming, R., 1310 Lean, M.E.J., 288 Lebovitz, H.E., C41 Lebrethon, M.-C., 1845 Lechi, A., 1536 Lechleitner, M., 1748 Lee, A.J., 453 Lee, E., 1715 Lee, E.T., 1802 Lee, R.H., 1914 Lee, W.-J., 1224 Lee, Y.-J., 1181 Lee, Z.S.K., 1450 Lefebvre, J., 1374 Lefèbvre, P.J., 1568 Legorreta, A.P., 752, 1487 Leiter, L.A., 913 Lemay, J.-F., 1592 Lemieux, I., 1471 Lemieux, S., 1471 Leone, J.P., 320 Leonetti, D.L., 1808 Leonhardt, W., 333 Leonnetti, D.L., 65 Leridon, L., 1621 Lernmark, Å., 409 Leslie, R.D.G., 1458 Lester, M.A., C14

Leung, K.-M., 752, 1487 Lev-Ran, A., 1906 Levetan, C.S., 1790 Levin, S., 1632 Levina, E.V., 1785 Levine, S.N., 1171 Levy, C.J., 1022 Levy, I., 1507 Lewy, V., 1325 Leydon, G.M., 856 Li, C.-L., 370 Li, J.K.Y., 1450, 2096 Li, S., 78 Lidar, M., 524 Lietz, T., 1008 Lièvre, M., 178 Lim, G., 1171 Lim, S.C., 1865 Limal, J.M., 618 Lin, A., 1501 Lin, J.C., 2104 Lin, Z., 1487 Lindahl, B., 1988 Lindberg, F.A., 1501 Lindholm, A., 801 Lindsay, R.S., 422 Lindström, T., 1373 Links, T.P., 198 Lipp, R.W., 368, 1920 Lipsky, M.S., 1929 Lipton, R.B., 78 Lithner, E, 409 Little, J., 422 Littorin, B., 409 Liu, J.-H., 861 Liu, L., 646 Liu, M.-L., 973 Lizzio, S., 2084 Lloyd, C.E., 1278 Lluch, I., 1378 Lobisch, M., 1296 Locatelli, F., 756 LoGerfo, F.W., 1865 Loi, C.-M., 2105 Lönnrot, M., 2086 López-Jiménez, L., 377 Lord, M., 1966 Lorini, R., 1591 Lormeau, B., 2044 Lounamaa, R., 1950 Lteif, A.N., 137 Lu, F.-H., 1938 Luft, 1., 294 Lutley, K.E., 635 Luzio, S.D., 394, 649 Lyden, E., 320 Lynch, J., 1999 M

Macdonald, I.A., 1144
Mace, J.W., 867
MacGregor, A.S., 453
Machecourt, J., 19
Mack-Shipman, L.R., 320
Mackay, I., B59
Mackay, I.R., 996
Madsbad, S., 1137, 1647
Maekawa, K., 818, 1851
Magee, M.E., 1802
Maggio, C.A., 191
Magnus, P., 1813
Magré, J., 1374
Mah, C.A., 1302

Main, E., 874 Mākimattila, S., 973 Makino, M., 1221 Malecki, M., 253 Malessa, R., 1296 Malik, R.A., 1839 Malini, P.L., 1586 Malmberg, K., B89, 1827 Manaka, H., 877, 920 Mandrup-Poulsen, T., 478 Mannucci, E., 368, 1755 Mansell, P., 1607 Manske, C.L., B109 Manto, A., 647 Mäntysaari, M., 973 Marbury, T.C., 789 Marciulionyte, D., 2086 Marcovina, S.M., 1165 Margolis, D.J., 692 Marre, M., B53, 178, 618 Marrero, D., 832 Marsh, J.B., 71 Marshall, J.A., 1632 Marshall, R.M., Jr., 202 Martha, P.M., Jr., 585 Martha, R.-M., 527 Martin, J.A., 729 Martin, P., 871 Martin-Vaquero, P., 1053 Martinez, S., 1507 Martinez-Triguero, M.L., 1378 Martini, A., 1591 Maruyama, T., 1759 Mason, P.E., 1206 Mason, R.P., 1206 Mason, S., 678 Massin, M.M., 1845 Mather, H.M., 933 Matsuda, M., 1462 Matsuhisa, M., 2072 Matsui, H., 1220 Matsumoto, K., 1191 Matsuoka, K., 615 Matthews, D., 1144 Matyka, K.A., 27, 1144 Mauro, L., 795 Mayer, G., 1530 Mayer-Davis, E.J., 1632 Mayfield, J.A., 1105 Mayou, R.A., 1956 Mbanya, J.N., 434 McAllister, A.S., 2061 McCance, D.R., 2061 McCarron, D.A., 191 McCarthy, M.1., 933 McCarty, D., B59 McCulloch, D.K., 382 McDermott, R., 1993 McDonnell, M.E., 1912 McElduff, A., 177 McEwen, J., 801 McFarland, K.F., 1561 McFarlane Anderson, N., 434 McGarvey, S.T., 1284 McGill, M., 598 McGwin, G., Jr., 220 McKeigue, P.M., 430 McKeown, R.E., 1561 McKinney, P.A., 928 McMahon, M., 191 McNeely, M.J., 65 McNitt, P.M., 1549

McPhee, S.J., 1302

McVie, R., 1171 Meadows, P.A., 1597 Medici, F., 1458 Medina, S., 426 Medlej, R., 1376 Mehlsen, J., 1186 Mehta, S.S., 1110 Meisner, C., 294 Melczer, Z., 870 Melki, V., 2089 Mellstrom, M., 678 Melton, L.J., III, 1479 Mendlowitz, D., 2011 Meneilly, G.S., 112, 1225 Meng, Y.-Y., 1487 Mercier, J., 1003 Merino, M.A., 1378 Metz, J. A., 191 Mevorach, M., 2026 Meza, M.P., 1325 Mezzetti, A., 1158 Michalik, D., 2011 Michishita, I., 355 Midthjell, K., 1813 Miki, T., 2094 Millauer, B.A., 933 Miller, D.K., 1596 Miller, S.J., 320 Minagawa, F., 355 Mingrone, G., 367 Mitchell, B.D., 938 Mittleman, M.A., 1999 Miwa, K., 2100 Mixon, P.S., 1517 Miyake, S., 1191 Miyamori, L., 484 Miyazaki, A., 1191 Mizutani, T., 1225 Mobley, C.C., 189 Moffitt, P., 119 Mogensen, C.E., B72 Mohamed-Ali, V., 363 Mohn, A., 27 Molina, A., 377 Moline, N., 2011 Molyneaux, L., 598, 1722 Monauni, T., 1536 Moore, W., 1 Moore, W.P.T., 2086 Mooy, J., 1097 Mora, C., 1006 Mori, M., 1228 Mori, Y., 908 Morii, H., 228, 818, 1851, 1858 Morillas, C., 1378 Morimoto, J., 1759 Morinaga, S., 615 Morley, J.E., 1596 Morris, C.D., 191 Moses, J., 535, 653, 874, 1059 Moses, R., 119 Moses, R.G., 535, 653, 874, 1059, 1747 Moss, S.E., 248, 743, 951, 1984 Motz, E., 1384, 2084 Mudaliar, S.R., 1501 Muggeo, M., 752, 1339, 1536, 1871 Mühlhauser, I., B29, C71 Mullen, P., 1598 Müller, U.A., B29 Muñoz, M.L., 1378 Muntoni, S., 179 Murakawa, Y., 908 Musliner, T.A., 1771

Myers, M.W., 2067 Mykkånen, L., 562, 1688 Mylvaganam, A., 1993

Nadeau, A., 1471 Nagachandran, P., 860 Nagai, Y., 1004 Nagasaka, A., 1221 Nagasaka, S., 523, 1911, 2088 Nagata, I., 2100 Nagata, M., 1221 Nagataki, S., 541 Naka, M., 1584 Nakai, Y., 1911, 2100 Nakamura, N., 1011, 1225, 1758 Nakamura, T., 523, 2088 Nakano, K., 1758 Nakaya, E., 1590 Namura, H., 152 Narayan, K.M.V., 271 Narita, T., 823 Nathan, D.M., 1785 Naum, C.C., 857 Navarro, J.F., 1006 Nawroth, P.P., 1227 Neil, A., 495, 1956 Nepom, G.T., 1517 Nerup, J., 478 Nespoli, L., 1590 Nesto, R.W., 1393 Newell-Morris, L., 1808 Newman, B., 938 Newson, R.B., 856 Newton, K., 382 Newton, R.W., 528 Ngogang, J.Y., 434 Nichol, J.M., 752 Nichols, G.A., 1116 Nicolson, M., 413 Nielsen, F.S., 478, 491 Nielsen, S., 1728 Nietzschmann, U., 1904 Nijpels, G., 1097 Nishino, M., 863 Nishizawa, Y., 818, 1851, 1858 Nissinen, A., 996, 1821 Nitter-Hauge, S., 45 Noakes, M., 889 Nohara, E., 1004 Nojima, K., 863 Nomura, G., 366 Norhammar, A.M., 1827 Norman, A., 1043 Norris, J.M., 1694 Northam, E.A., 1438 Northern California Kaiser Permanente

O O'Brien, P.C., 1479 O'Dea, K., 555, 1993 O'Keeffe, C., 253 O'Shea, D., 178, 370 Oberhollenzer, F., 1339 Obermayer-Pietsch, B., 1920 Odekerken, D.A.M., 125 Oesterle, A., 1779 Offenbacher, S., 767 Ogihara, T., 863, 2094 Ognibene, A., 368

Diabetes Registry, 933

Noso, S., 863

Nozue, T., 355

Ohnuma, H., 877 Oida, K., 484 Okada, E., 484 Okada, K., 228, 908, 1432, 1683 Okamura, C., 1382 Oksa, H., 1747 Okumura, K., 1220 Okuno, Y., 818 Oliveira, J., 1599 Ollerton, R.L., 394, 649 Olmedilla Alonso, B., 870 Onkamo, P., 2092 Ono, M., 863 Ono, Y., 877 Ooi, C., 1598 Oparil, S., 191 Oppenheim, U., 328 Oranje, W.A., 2083 Orban, T., 253 Orchard, T.J., 1084, 1220 Ordóñez, J., 812 Orsatti, C., 1590 Orth-Gomér, K., 1999 Osei, K., 1588, 1594 Östenson, C.-G., 1043 Østerby, R., 314, 478 Östergren, J., 147 Ostman, J., 409 Ottervanger, J.P., 647 Ovalle, F., 859, 1000, 1921 Owen, R., 913 Owens, D.R., 394, 649 Oxford Regional Prospective Study Group, 495 Ozaki, H., 2072

Pacaud, D., 1592 Pachter, L.M., 722 Padfield, P.L., 422 Pagano, G., 50, 652 Pallardo, F., 1053, 2085 Palmer, J.P., 1517 Palomba, E., 1587 Pampanelli, S., 468, 795 Pan, X.-M., 300 Panelo, A., 1458 Pantelejeva, O., 1428 Papadodima, E.L., 859 Paradies, K., 569 Paradisi, G., 1310 Park, G., B109 Parslow, R., 928 Parving, H., 476, 491 Parving, H.-H., B76 Pascot, A., 1471 Passaro, M.D., 1790 Patrizia, C., 1379 Patterson, C., 1698 Pattou, E, 1374 Paultre, C.Z., 388 Pavlovic, M., 1151 Payne, C., 362 Peart-Vigilance, C., 1408 Pecis, M., 1512 Pedersen, T.R., 1771 PEDIAB Collaborative Group, 1445 Pedrosa, L.F.C., 362 Pedula, K., 1011 Penny, A., 933 Pénzes, J., 533 Peppard, H.R., 1549

Pérez, A., 812

Perez-Martin, A., 1003

Perlmuter, L.C., 1918 Perry, H.M., III, 1596 Perry, I.J., 1382, 1919 Perry, R.C., 883 Persson, P.-G., 1043 Peters, A.L., 532 Peterson, D.L., 874 Pettitt, D.J., 944, 1422 Peveler, R.C., 1956 Peyrot, M., 448 Pfützner, A., 784, 1760 Phillips, L.S., 661, 1415, 1494, 1617 Pi-Sunyer, EX., 191 Piantanida, E., 1590 Piedmont Study Group for Diabetes Epidemiology, 50 Piers, L.S., 555 Piette, J.D., 1302 Piitulainen, A., 1961 Pinget, M., 1001 Pinzur, M.S., 2099 Pitei, D.L., 1966 Pitkāniemi, J., 1066 Pitocco, D., 647 Pittenger, G.L., 1839 Platts, J.K., 1597 Playle, R., 394, 649 Podar, T., 2092 Poehlman, E.T., 1875 Poisson, D., 667 Polak, M., 1621 Pomerleau, J., 430 Popp, G., 1549 Potts, R.O., 1708 Poulsen, P.L., B72 Pourmotabbed, G., 1524 Pouwer, F., 2004 Powe, N.R., 1660 Pozzilli, P., 1458 Prager, R., 1530 Pratt, I.A., 700 Pressler, H., 294 Preston, R.A., 982 Pricemb, J.F., 453 Prineas, R.J., 1092 Prud'homme, D., 1471 Psaty, B.M., 736 Puhl, U., 865 Puig, M., 371 Pulley, L., 220 Purnell, J.Q., 1165 Putt, R.S., 555 Puukka, P., 1196 Pyorala, K., 86, 1385, 1771

Q Qiao, Q., 1821 Quattrin, T., 585 Quigley, M., 1022

Raatz, S.K., 896 Rabasa-Lhoret, R., 667 Rabensteiner, D., 1530 Rachmani, R., 524 Rahko, J., 2086 Raile, K., 1904 Rajbhandari, S.M., 1292 Rakic, M., 125 Ramachandran, A., 175 Ramsey, S.D., 382 Rashin, L., 1906 Rasmussen, M.L., 1077

### **AUTHOR INDEX 1999**

Rassam, A.G., 133, 2037 Ratanasuwan, T., 320 Ratner, R.E., 1790 Rave, K., 865 Ravelli, A., 1591 Ravid, M., 524 Ravussin, E., 413 Raynaud, E., 1003 Reaven, G.M., 179 Redmon, J.B., 896 Reeds, P., 806 Reeser, H.M., 1749 Regensteiner, J.G., 1640 Reiber, G.E., 157, 382 Reijonen, H., 1950 Reinauer, K.M., B29 Reitsma, W.D., 198 Remsberg, K.E., 1561 Renard, E., 1001, 1371 Renier, G., 529 Renner, R., 784 Resnick, L. M., 191 Reunanen, A., 575 Reusch, J.E.B., 1640 Reusser, M.E., 191 Rewers, M., 562, 1694 rhIGF-I in IDDM Study Group, 585 Ricardo, A.-R., 527 Ricart, W., 525, 868 Riccardi, G., 1490 Rice, B., 684 Ricerca, B.M., 647 Richter, E.A., 1330 Richton, S., 700 Riddle, M.C., C76 Rideout, J.A., 208 Rigalleau, V., 1002 Riis, A.P., 801 Rissanen, A., 575 Risse, A., B29, 674 Riste, L., 434 Rith-Najarian, S., 441 Ritse, M.J., 1919 Ritz, E., B80 Rivellese, A.A., 1490 Rix, M., 827 Roach, P., 1258 Robbins, D.C., 1715, 1802 Roberts, W.L., 369 Robertson, R., 1325 Robinson, A., 528 Robinson, S., 933 Rocour-Brumioul, D., 1845 Røder, M.E., 609 Rodriguez, B.L., 1262 Rodriguez, R., 202 Rogantin, F., 176 Roguin, A., 860 Rokkaku, K., 523 Roller, R.E., 1920 Roller, S., 2011 Rondas-Colbers, G.J.W.M., 2083 Rönnemaa, T., 1196 Roseman, J.M., 220 Rosenbloom, A.L., 345 Rosenfield, R.L., 141 Roslin, M.S., 651 Ross, K.M., 27 Ross, R., 684 Ross, S., 603 Rossing, P., 478, 491 Rosskamp, R.H., B109 Rotella, C.M., 368, 1755

Rottmann, M., 674 Rovellini, A., 372 Rowell, S.E., 938 Rowley, K.G., 1993 Rowley, M., B59 Rowley, M.J., 996 Rubin, R.R., 448, 832 Ruderman, N.B., 1912 Ruffa, G., 1490 Ruhnau, K.-J., 1296 Ruige, J.B., 213, 1097 Russo, A., 2084 Ryan, C.M., 1239 Ryden, L., 1827

S Saad, M.F., 562 Saaddine, J., 271 Saavedra, G.A., 1916 Sacchetti, C., 1587 Sacerdote, A.S., 861 Sadler, M., 1318 Sadur, C.N., 2011 Safran, M.A., 508 Saggiani, E, 1536 Saint-Paul, M., 1361 Saito, T., 523, 877, 2088 Sakai, M., 1911, 2100 Salado, E.V., 1905 Salamon, F., 870 Salmi, J., 1747 Salti, I., 1376 Salvatoni, A., 1590 Samaras, K., 1401 Sampson, M.J., 1626 Samsom, M., 339 Sandberg, M.I., 1004 Sandhu, N., 382 Sandler, L., 1226 Sandler, S., B121 Sandvik, L., 45, 1386 Sarelin, L., 1347 Sarlund, H., 86 Saruta, T., 1759, 1910 Sasso, F.C., 1217 Sato, A., 491 Satyavani, K., 175 Saudek, C.D., C45, 1660 Sauter, K., 784

Savin, B., 1396
Savola, K., 1950
Sawyer, M., 1933
Scandinavian Simvastatin Survival Study
Group, 1771
Schade, D.S., 133, 2037
Schaper, F., 333
Scheen, A.J., 1568
Scheen, A.J., 1568
Schenck-Gustafsson, K., 1999
Schlenzka, A., 973
Schlossman, D.K., 1245
Schmidt, M.L., 767, 1077

Savage, P.L., 562, 736, 767, 1769

Schlossman, D.K., 1245 Schmidt, M.I., 767, 1077 Schneidt, W.J., 368, 1920 Schneider, M.S., 1672 Schneiderman, N., 1092 Schnoell, F., 1882 Schranz, A.G., 650 Schulman, K.A., 1110

Schultz, C.J., 495 Schulz, L.O., 413 Schuster, D.P., 1588, 1594 Schütte, K., 1296 Schwartz, R., 1201 Schweiger, A., 1904 Schweizer, H.P., 294 Schwenger, V., B80 Schwenk, W.E., 137 Scotti, S., 253 Sedman, A.J., 2105 Seino, H., 1754 Sekikawa, A., 920 Selby, J., 562 Selby, J.V., 38, 938, 2011 Selmo, V., 2084 Senan, C., 1361 Seppala-Lindroos, A., 2055 Serri, O., 529 Service, E.J., 1479

Sewell, A., 280 Shaffer, T., 1660 Shamoon, H., 2026 Shaper, A.G., 1266 Sharpe, D.S., 1262 Sharp, D.S., 1262 Sharp, L.K., 1929 Shaw, J.E., 399, 762 Shaw, K.H., 700 Sherif, K.D., 71 Sherman, S.H., 779 Sheu, W.H.-H., 1224 Shimada, A., 615, 1759, 1910 Shimizu, H., 1071, 1228 Shin, S.-J., 1181 Shintani, M., 863

Shini, S.-J., 1181 Shin, S.-J., 1181 Shintani, M., 863 Shofer, J.B., 65, 1808 Shoji, T., 818, 1851, 1858 Sibley, S.D., 1165 Siegert, G., 333 Sievenpiper, J.L., 913 Sijbrands, E.J.G., 125 Silkar, R., 1 Silberbusch, J., 125 Sillamåkt-Ojansuu, U., 1747 Silveiro, S.P., 1745

Simoes, E., 1703 Simon, D., 1361 Simon, L.P. 208 Simone, E.A., B7 Simonson, D.C., 1022 Sims, R.V., 220 Singer, E., 1757 Sirolla, C., 2033 Sivasankari, S., 175 Skjåk-Braek, G., B121 Skyler, J.S., 1092 Slaats, E.H., 125 Slobodniuk, R., 119 Sluiter, W.J., 198 Smakowski, P., 1865 Smit, A.J., 198

Smakowski, P., 1865 Smit, A.J., 198 Smith, D.G., 157, 1029, 1036 Smith, L., 1310 Smith, N.L., 736 Smith, R.L., 1909 Smits, P., 1048, 1752 Smulders, Y.M., 125 Snehalatha, C., 175 Snoek, F.J., 2004 Snorgaard, O., 1186 Snyder, G.W., 191 Sobhy, T.A., 2037 Sodoyez-Goffaux, F., 609 Soler, J., 377 Solfelix, C.M., 1458 Soltesz, G., 1698

Somani, B.L., 366 Sommariva, D., 372 Sondern, K., 674 Sørensen, S., B97 Sosenko, J.M., 1715 Souche, C., 1371 Southon, S., 1626 Sovik, O., B40 Sowers, J.R., C14 Spadafora, P., 913 Sparling, Y.H., 1715 Speer, G., 870 Spencer, R., 598 Stach, B., 1008 Stacpoole, P.W., 532 Stalenhoef, A.F.H., 1752 Stalenhoef, A.H., 371 Stang, M.R., 925 Stansberry, K.B., 1549 Staprans, I., 300, 1385 Steen-Müller, M.K., 1832 Steer, P.J., 933 Steffes, M.W., 1165 Stehouwer, C.D.A., 125, 1097 Steinberg, H.O., 1310 Steiner, G., C6 Stella, P., 876 Stender, M., 2067 Stensel, V., 1036 Stenström, G., 773 Stern, J.S., 191 Stern, M.P., C2, C57, 844, 1655 Stolk, R.P., 180, 213 Storti, S., 647 Strack, T., 603 Strange, P., 1501 Stratta, R.J., 320 Stratton, I., 495 Strocchi, E., 1586 Strollo, F., 367 Strollo, G., 367 Suematsu, C., 228, 1432, 1683 Sullivan, D., 1401 Summanen, P., 973 Sumner, A.E., 71 Sundkvist, G., 409, 593, 773, 1907, 1913, 1944 Suryapranata, H., 647 Sutton, D.R., 1 Suzuki, R., 1759, 1910 Suzuki, S., 1110 Svanström, L., 1043 Svensson, H., 593 Swain, B.E., 38, 2011 Swanson, J.E., 896 Swennen, G.N.M., 2083 Syvanne, M., 973 Szelag, B., 1907

T Tabák, Á.Gy., 533, 876 Taboga, C., 2084 Tack, C.J.J., 1752 Tada, H., 484 Tajima, N., 908 Takahashi, S., 484 Takala, J.K., 997 Takamura, T., 1004 Takatsuka, N., 1071 Taketoh, H., 152 Tallsund, M., 1845 Tamada, J.A., 1708 Tamás, G., 533, 876

Tamborlane, W.V., 1779 Tan, B.-Y., 241 Tan, C.-E., 241 Tanaka, H., 1911 Tang, J., 1751 Tani, A., 2072 Taniguchi, A., 1911, 2100 Taniguchi, T., 152 Taniwaki, H., 1851, 1858 Targher, G., 1871 Tarnow, L., 478, 491 Tasaka, Y., 1590 Taskinen, M.-R., 973, 1347 Taylor, J., 1933 Taylor, R., 320 Tchernof, A., 1471, 1875 Temelkova-Kurktschiev, T.S., 333 Teramo, K.A., 1201 Tesfaye, S., 1292 Thaler, L.M., 1415 Thaulow, E., 45 Theiss, T., 874 Thelen, M.H., 294 Thibult, N., 1361 Thivolet, C., 388 Thomas, K., 647 Thomas, W.T., 896 Thon, A., 1151, 1555 Thordarson, H., B40 Thorsby, P., 1543 Thotathuchery, M., 806 Thrailkill, K.M., 585 Thye-Rønn, P., 546 Tibbs, T.L., 1887 Tillmanns, H., 1832 Timsit, J., 1584 Todaro, L., 647 Toeller, M., B21 Toft-Nielsen, M.-B., 1137 Tohda, G., 484 Toki, Y., 1220 Tokuyama, K., 1911, 2100 Tom, E., 208 Tominaga, M., 920 Tominaga, Y., 1191 Tonutti, L., 2084 Torella, R., 1217 Torjesen, P.A., 1186 Torlone, E., 468, 795 Torri, A., 372 Tortul, C., 1755 Toth, M.J., 1875 Tovo, P.A., 1587 Tracy, R., 562 Tracy, R.P., 1688 Trautmann, M., 784 Tremblay, A., 1471 Treskes, M., 125 Treviño, R.P., 202 Trief, P.M., 569 Trinker, M., 368 Tritschler, H., 1227 Tritschler, H.J., 280 Trotter, R.T., 722 Trovati, M., 50 Tsai, J.-H., 1181 Tsai, S.-T., 370 Tsang, L.W.W., 2096 Tsuchiya, T., 1228 Tsui, E., B35 Tsui, E.Y., 1216 Tsuji, H., 1382

Tsumura, K., 228, 1432, 1683

Tsutsui, T., 863
Tubiana-Rufi, N., 1445, 1621
Tucker, R., 1284
Tulenko, T.N., 71
Tumini, S., 1158
Tuomi, T., 1347
Tuomilehto, J., 399, 996, 1066, 1821, 1961, 2092
Tuomilehto-Wolf, E., 996, 2092
Tuominen, J.A., 459
Tuominen, J.T., 1196
Turco, S., 1217
Turner, R., B59
Turner, R.C., 543, 960
Tverdal, A., 1813

U
Ubels, FL., 198
Uchimura, K., 1221
Ueda, H., 863
Ueda, N., 2072
Ueki, Y., 1191
UKPDS Study Group, 960, 1125
Umpierrez, G.E., 1517
Urbonaite, B., 2086
Usadel, K.H., 280

Vaccaro, O., 1490 Vague, P., 1396 Vakkilainen, J., 973 Valdez, R., 441 Valencia, M.E., 413 Valensi, P., 2044 Valle, T., 575, 1821 Van Breda, S.G.J., 1749 van Dam, R.M., 1919 van der Does, F.E., 904 van der Ploeg, H.M., 2004 van Eijk, J.T., 904 Van Gils, C.C., 678 Van Maanen, J.M.S., 1749 van Rijn, H.J.M., 864 Vanamo, R., 528 Vanelli, M., 7, 1158 Vantyghem, M.-C., 1374 Vanzetto, G., 19 Vaysse, J., 2044 Vašků, A., 1745 Vašků, V., 1745 Veglio, M., 50 Vehkavaara, S., 2055 Velussi, M., 1755 Vendrell, J., 525, 868 Venkat Narayan, K.M., 1769 Verbeek, A.L., 1048 Verhage, B., 1048 Verlato, G., 756 Verrotti, A., 1158 Versace, A., 1587 Vervoort, G., 1048 Vessby, B.O.H., 10 Vestergaard, H., 609 Veves, A., 1865 Vibe-Petersen, J., 1647 Vice, P.A., 2101 Vicini, P., 280 Vidgen, E., 913 Vigouroux, C., 1374 Vijay, V., 175 Vileikyte, L., 157, 1428 Vilja, P., 2086 Villalobos, E.R., 1905

Vineis, P., 652 Vinicor, F., 508 Vinik, A.I., 1549, 1839 Virta-Autio, P., 1961 Virtanen, S.M., 1961 Vlachou, E.D., 859 Vohr, B.R., 1284 Vølund, A., 1063 Voss, M., B29 Voss, R., 1832 Vuksan, V., 913

# W

Waas, W., 1832 Wagner, A., 371, 674 Wägner, A.M., 812, 2099 Wagner, E.H., 382 Wahl, P.W., 1808 Wai, H.P.S., 1751 Wakasaki, H., C31 Waldecker, B., 1832 Walker, J.D., 422 Walker, K.Z., 555 Walsh, K., 288 Wamala, S.P., 1999 Wang, Y., 233 Wannamethee, S.G., 1266 Ward, B., 874 Ward, J.D., B84, 1292 Wareham, N.J., 262 Warne, G.L., 1438 Warram, J.H., 253 Watanabe, N., 152 Waters, J., 1 Watkins, P., 998 Watkins, P.J., 1966 Watson, R., 2011 Webb, S.M., 2099 Wegmann, D.R., B7 Weigle, D.S., 65 Weinberger, M., 1302 Weinehall, L., 1988 Weinger, K., 1022 Weinstock, R.S., 569 Weitgasser, R., 1882 Weitzman, S., 2104 Weller, S.C., 722 Weller, W.E., 1660 Welty, T., 1715 Welty, T.K., 1802 Wendorf, M., 176 Wenzl, H.H., 1920

Werther, G.A., 1438 Westerbacka, J., 2055 Wetzels, J.F., 1048 Weyer, C., 865 Wheeler, C.G., 678 Wheeler, L.A., 678 Whitcomb, R., 1384 White, H., 1318 Whitecotton, L., 1105 Wibell, L., 409 Wienhausen-Wilke, V., 674 Wilks, R., 434 Willeit, J., 1339 Willems, H., 1048 Williams, A.J.K., 1796, 2049 Williams, C.B., 418 Williams, G., 1598 Williams, K.V., 1084 Williams, R., 262, 928 Williams-Cleaves, B., 1524 Wilson, D.M., 1479 Wilson, S., 1966 Windfeld, K., 789 Winkler, G., 870 Winter, W.E., 345 Wishart, J.M., 503 Wishner, W.J., 635 Witteman, J.C.M., 213 Wójcicki, J.M., 854 Wolffenbuttel, B.H.R., 463, 1749, 2083 Wolfsdorf, J.L., 1767 Wolkotte, C., 1048 Wollesen, F., 93 Wollmer, P., 593 Wong, W.W., 806 Woo, W., 1517 Woods, H.F., 1010 Woodworth, J.R., 865 Wozniak, R., 2026 Wroblewski, M., 593, 1907 Wu, C.-H., 1938 Wu, J.-S., 1938 Wu, K.K., 767 Wu, M.M.E, 1751 Wysowski, D.K., 925

# X

Xiang, K., 646

# Y

Yajima, Y., 523 Yajnik, C.S., 363 Yale, J.-F., 1592 Yamada, K., 863, 2094 Yamada, S., 152 Yamaguchi, H., 877 Yamaguchi, M., 1382 Yamaguchi, Y., 541 Yamamoto, M., 2072 Yamasaki, Y., 2072 Yamashita, H., 1004 Yamauchi, K., 1584 Yamazaki, T., 1754 Yang, Y., 253 Yano, K., 1262 Yano, M., 1191 Yao, W.-J., 1938 Yeung, V.T.F., 1450, 2096 Yki-Järvinen, H., 973, 2055 Ylihärsilä, H., 996 Yokoyama, J., 908 Yoneda, H., 2094 Yoneda, N., 152 Yoneshima, M., 366 Yoo, W., 645 Yoshida, S., 1754 Yoshinari, M., 1382 Yoshino, G., 1176, 1917 Yoshizawa, K., 1584 Young, R.S., 345 Young-Hyman, D., 580 Young-Hyman, D.L., 2018 Yu, D., 418 Yu, L., 1694 Yudkin, J.S., C25, 363 Yue, D.K., 598, 1722 Yue, L., 1258 Yusuf, S., 233

# 7

Zahejský, J., 1745
Zawacki, C.M., 418, 1017
Zeise, T.M., 133, 2037
Zelmanovitz, T., 1599
Zenere, B.M., 1536
Zenti, M.G., 1536
Ziegler, D., 1296
Ziegler, R., 1227
Ziemer, D.C., 1415, 1494, 1617
Zijlstra, F., 647
Zimmet, P., 859, 996, 1092
Zimmet, P.Z., 399, 762
Zinman, B., B35, 524, 603, 1216, 2095
Zoppini, G., 756, 1871